<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic antagonists for people with chronic obstructive pulmonary disease - Sliwka, A - 2018 | Cochrane Library</title> <meta content="Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic antagonists for people with chronic obstructive pulmonary disease - Sliwka, A - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012355.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic antagonists for people with chronic obstructive pulmonary disease - Sliwka, A - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012355.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012355.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic antagonists for people with chronic obstructive pulmonary disease" name="citation_title"/> <meta content="Agnieszka Sliwka" name="citation_author"/> <meta content="Jagiellonian University Medical College" name="citation_author_institution"/> <meta content="Milosz Jankowski" name="citation_author"/> <meta content="Jagiellonian University Medical College" name="citation_author_institution"/> <meta content="Iwona Gross‐Sondej" name="citation_author"/> <meta content="The University Hospital in Krakow" name="citation_author_institution"/> <meta content="Monika Storman" name="citation_author"/> <meta content="Systematic Reviews Unit Polish Cochrane Branch (Cochrane Poland)" name="citation_author_institution"/> <meta content="Roman Nowobilski" name="citation_author"/> <meta content="Jagiellonian University Medical College" name="citation_author_institution"/> <meta content="Malgorzata M Bala" name="citation_author"/> <meta content="Jagiellonian University Medical College" name="citation_author_institution"/> <meta content="gosiabala@mp.pl" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD012355.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/08/24" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012355.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012355.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012355.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Inhalation; Adrenal Cortex Hormones [*administration &amp; dosage]; Adrenergic beta-2 Receptor Agonists [*administration &amp; dosage]; Androstadienes [administration &amp; dosage]; Benzyl Alcohols [administration &amp; dosage]; Chlorobenzenes [administration &amp; dosage]; Drug Administration Schedule; Forced Expiratory Volume; Muscarinic Antagonists [*administration &amp; dosage]; Pulmonary Disease, Chronic Obstructive [drug therapy]; Quality of Life; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012355.pub2&amp;doi=10.1002/14651858.CD012355.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012355.pub2&amp;doi=10.1002/14651858.CD012355.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012355.pub2&amp;doi=10.1002/14651858.CD012355.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012355.pub2&amp;doi=10.1002/14651858.CD012355.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012355.pub2&amp;doi=10.1002/14651858.CD012355.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012355.pub2&amp;doi=10.1002/14651858.CD012355.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012355.pub2&amp;doi=10.1002/14651858.CD012355.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012355.pub2&amp;doi=10.1002/14651858.CD012355.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012355.pub2&amp;doi=10.1002/14651858.CD012355.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012355.pub2&amp;doi=10.1002/14651858.CD012355.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012355.pub2&amp;doi=10.1002/14651858.CD012355.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012355.pub2&amp;doi=10.1002/14651858.CD012355.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012355.pub2&amp;doi=10.1002/14651858.CD012355.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012355.pub2&amp;doi=10.1002/14651858.CD012355.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012355.pub2&amp;doi=10.1002/14651858.CD012355.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012355.pub2&amp;doi=10.1002/14651858.CD012355.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012355.pub2&amp;doi=10.1002/14651858.CD012355.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012355.pub2&amp;doi=10.1002/14651858.CD012355.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012355.pub2&amp;doi=10.1002/14651858.CD012355.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012355.pub2&amp;doi=10.1002/14651858.CD012355.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012355.pub2&amp;doi=10.1002/14651858.CD012355.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012355.pub2&amp;doi=10.1002/14651858.CD012355.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012355.pub2&amp;doi=10.1002/14651858.CD012355.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="l7AWCCEw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012355\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012355\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012355\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012355\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ms","fr","pl","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012355.pub2",title:"Once\\u2010daily long\\u2010acting beta\\u2082\\u2010agonists/inhaled corticosteroids combined inhalers versus inhaled long\\u2010acting muscarinic antagonists for people with chronic obstructive pulmonary disease",firstPublishedDate:"Aug 24, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=l7AWCCEw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012355.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012355.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012355.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012355.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012355.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012355.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012355.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012355.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012355.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012355.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2389 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012355.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/full#CD012355-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/full#CD012355-sec-0094"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/full#CD012355-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/full#CD012355-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/full#CD012355-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/full#CD012355-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/full#CD012355-sec-0061"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/full#CD012355-sec-0088"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/appendices#CD012355-sec-0099"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/table_n/CD012355StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/table_n/CD012355StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic antagonists for people with chronic obstructive pulmonary disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/information#CD012355-cr-0002">Agnieszka Sliwka</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/information#CD012355-cr-0003">Milosz Jankowski</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/information#CD012355-cr-0004">Iwona Gross‐Sondej</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/information#CD012355-cr-0005">Monika Storman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/information#CD012355-cr-0006">Roman Nowobilski</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012355.pub2/information#CD012355-cr-0007"><i class="icon corresponding-author fa fa-envelope"></i>Malgorzata M Bala</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/information/en#CD012355-sec-0108">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 24 August 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012355.pub2">https://doi.org/10.1002/14651858.CD012355.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012355-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012355-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012355-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012355-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012355-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012355-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012355-abs-0001" lang="en"> <section id="CD012355-sec-0001"> <h3 class="title" id="CD012355-sec-0001">Background</h3> <p>Three classes of inhaler medication are used to manage chronic obstructive pulmonary disease (COPD): long‐acting beta₂‐agonists (LABA); long‐acting muscarinic antagonists (LAMA); and inhaled corticosteroids (ICS). To encourage patient adherence, two classes of medication are often combined in a single medication device; it seems that once‐daily dosing offers greatest convenience to patients and may markedly influence adherence. </p> </section> <section id="CD012355-sec-0002"> <h3 class="title" id="CD012355-sec-0002">Objectives</h3> <p>To compare a once‐daily combination of inhaled corticosteroid and long‐acting beta₂‐agonist inhalers (ICS/LABA) versus inhaled long‐acting muscarinic antagonists alone (LAMA) for people with chronic obstructive pulmonary disease (COPD). </p> </section> <section id="CD012355-sec-0003"> <h3 class="title" id="CD012355-sec-0003">Search methods</h3> <p>We performed an electronic search of the Specialised Register of the Cochrane Airways Group (14 May 2018), ClinicalTrials.gov (14 May 2018), and the World Health Organization International Clinical Trials Registry Platform (20 September 2017), then a search of other resources, including reference lists of included studies and manufacturers' trial registers (10 October 2017). Two pairs of review authors screened and scrutinised selected articles. </p> </section> <section id="CD012355-sec-0004"> <h3 class="title" id="CD012355-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) comparing once‐daily administered ICS/LABA and LAMA in adults with COPD. </p> </section> <section id="CD012355-sec-0005"> <h3 class="title" id="CD012355-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data and assessed risk of bias in each study. We analysed dichotomous data as random‐effects odds ratios (ORs) and continuous data as mean differences (MDs), both with 95% confidence intervals (95% CIs), using Review Manager 5. </p> </section> <section id="CD012355-sec-0006"> <h3 class="title" id="CD012355-sec-0006">Main results</h3> <p>We included two studies with 880 participants. We identified one ongoing trial with planned recruitment of 80 participants. Included studies enrolled participants with both partially reversible and non‐reversible COPD and baseline mean per cent predicted (%pred) forced expiratory volume in one second (FEV₁) of 43.4 to 49.6. Both studies lasted 12 weeks. Both studies used the same combination of inhaled ICS/LABA (fluticasone furoate and vilanterol 100/25 mcg once daily; FF/VI) versus LAMA (18 mcg tiotropium; TIO). They were published as full articles, and neither study was at low risk of bias in all domains. </p> <p>Compared to the TIO arm, results for pooled primary outcomes for the FF/VI arm were as follows: mortality: OR 0.20, 95% CI 0.02 to 1.73, 880 participants (deaths reported only in the TIO arm), very low‐quality evidence; COPD exacerbation (requiring short‐burst oral corticosteroids or antibiotics, or both): OR 0.72, 95% Cl 0.35 to 1.50, 880 participants, very low‐quality evidence; pneumonia: reported in both studies only during treatment with FF/VI: OR 6.12, 95% Cl 0.73 to 51.24, 880 participants, very low‐quality evidence; and total serious adverse events: OR 0.96, 95% Cl 0.50 to 1.83, 880 participants, very low‐quality evidence. None of the pneumonias were fatal. Compared to the TIO arm, we found no statistically significant difference for pooled secondary outcomes, including St George's Respiratory Questionnaire (SGRQ) mean total score change; hospital admissions (all‐cause); disease‐specific adverse events; mean weekly rescue medication use (results available from only one of the studies); and mean weekly percentage of rescue‐free days for FF/VI. We found no statistically significant differences between ICS/LABA and LAMA for improvement in symptoms measured by the COPD Assessment Test (CAT score) nor for FEV₁ (change from baseline trough in 24‐hour weighted mean on treatment day 84). Many pooled estimates lacked precision. Data for other endpoints such as exacerbations leading to intubation and physical activity measures were not available in included trials. </p> </section> <section id="CD012355-sec-0007"> <h3 class="title" id="CD012355-sec-0007">Authors' conclusions</h3> <p>Based on analysis of primary and secondary outcomes, we are uncertain whether once‐daily ICS/LABA, combined in one inhaler, has a different efficacy or adverse effect profile compared to LAMA for treatment of people with COPD. However, the current review is based on only two trials with the main focus on primary outcomes other than those considered in this review. The short follow‐up period and the very low quality of evidence limit our confidence in the result and increase uncertainty. Further trials of longer duration are needed. Current evidence is not strong enough to demonstrate important differences between inhalers in terms of effects, nor to establish that once‐daily fluticasone/vilanterol 100/25 mcg and tiotropium 18 mcg are equivalent. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012355-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012355-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012355-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012355-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012355-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012355-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012355-abs-0010">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012355-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012355-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012355-abs-0005" lang="en"> <h3>Is once‐daily ICS/LABA combined in one inhaler more beneficial than inhaled LAMA for treatment of people with COPD? </h3> <p><b>Background</b> </p> <p>Chronic obstructive pulmonary disease (COPD) is a lung disease that includes chronic bronchitis and/or emphysema. Symptoms include breathlessness and long‐term cough. COPD cannot be cured, but its symptoms are treatable. </p> <p>Three classes of inhaler medication are used to manage COPD, each acting in a different way: long‐acting beta₂‐agonists (LABA, e.g. vilanterol); long‐acting muscarinic antagonists (LAMA, e.g. tiotropium); and inhaled corticosteroids (ICS, e.g. fluticasone). To try to make it easier for people to take their medications, inhalers that combine treatments have been developed. We wanted to find out if using a combined inhaler containing ICS and LABA once a day is better or worse than taking a LAMA inhaler alone. </p> <p><b>Study characteristics</b> </p> <p>We found two studies involving 880 participants that compared the benefits and harms of once‐daily inhaled ICS/LABA combined in one inhaler versus inhaled LAMA for treatment of adults with COPD. These studies lasted 12 weeks. Participants were men and women aged 40 or older who had COPD with various degrees of severity. </p> <p><b>Key results</b> </p> <p>No consistent differences were found between the two different types of inhalers included in this review. Researchers reported no major differences in death rate, numbers of COPD exacerbations, lung inflammation, or other serious unwanted events. <br/> People receiving both inhalers showed similar improvements in quality of life, symptoms, and lung function tests. </p> <p><b>Quality of the evidence</b> </p> <p>Overall, we assessed the evidence presented in this review to be of very low quality, which means we have very little confidence in the findings. The main reasons for such judgement include the small number of identified studies and the fact that these studies were not focused on the outcomes of interest for this review. Also, both studies had a short observation time, which means that most of the undesired events may have occurred after the observation period was over. </p> <p><b>Bottom line</b> </p> <p>From this review, we did not find evidence strong enough to demonstrate major differences between inhalers or to establish that these inhalers have the same effect. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012355-sec-0094" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012355-sec-0094"></div> <h3 class="title" id="CD012355-sec-0095">Implications for practice</h3> <section id="CD012355-sec-0095"> <p>Only two relevant randomised controlled trials (RCTs) have been published to date. Both compared the combination of inhaled corticosteroids (ICS)/long‐acting beta₂‐agonists (LABA) ‐ fluticasone and vilanterol 100/25 mcg once daily ‐ versus a long‐acting muscarinic antagonist (LAMA) ‐ 18 mcg tiotropium; both trials were of short duration and focused on different primary outcomes than were included in our review. </p> <p>Very low‐quality evidence does not allow us to be certain that there are important differences, or equivalence, in effects between once‐daily ICS/LABA combined inhalers and long‐acting LAMA in patients with chronic obstructive pulmonary disease (COPD). Our confidence is reduced primarily by the imprecision of effect estimates and concerns about the methodological quality of the included studies. However the included trials were not powered to detect differences in clinically important outcomes, such as mortality, hospital admissions, exacerbations, and other undesirable effects or quality of life; therefore more trials with longer follow‐up that are focused on patient‐important outcomes are needed. </p> </section> <h3 class="title" id="CD012355-sec-0096">Implications for research</h3> <section id="CD012355-sec-0096"> <p>RCTs with complete follow‐up of at least 12 months are required to compare once‐daily combination ICS/LABA inhalers versus inhaled LAMA in people with COPD. It is suggested that future studies should be designed to take into account the primary and secondary patient‐centred outcomes typical for COPD (e.g. mortality, COPD exacerbation, pneumonia, other serious adverse events as primary outcomes; quality of life, hospital admissions, exacerbations leading to intubation, disease‐specific adverse events as secondary outcomes). Given that the aims of included studies were not directly dedicated to assessment of effects of the active substance on primary endpoints important in COPD, a comparative study of fluticasone and vilanterol 100/25 mcg once daily versus tiotropium 18 mcg once daily would be valuable. However, in view of the rapid advances in pharmacology dedicated to this group of patients, it is important to take into account what active substances and concentrations will be applied in inhalers used once a day. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012355-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012355-sec-0029"></div> <div class="table" id="CD012355-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Once‐daily ICS/LABA combined inhalers compared to once‐daily LAMA for people with chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Once‐daily ICS/LABA combined inhalers compared to once‐daily LAMA for people with chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with chronic obstructive pulmonary disease<br/> <b>Setting:</b> studies were conducted at 102 medical centres in 11 countries (Canada, Czech Republic, Germany, Poland, Romania, USA, Argentina, France, Italy, Norway, Russian Federation, Ukraine)<br/> <b>Intervention:</b> once‐daily inhaled corticosteroids/long‐acting beta₂‐agonists combined inhalers (FF/VI)<br/> <b>Comparison:</b> inhaled long‐acting muscarinic antagonist (TIO) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with inhaled long‐acting muscarinic antagonist (TIO)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers (FF/VI)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality (all‐cause)<br/> Follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.20<br/> (0.02 to 1.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>880<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any COPD exacerbation that requires short‐burst oral corticosteroids or antibiotics, or both<br/> Follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000<br/> (15 to 60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.72<br/> (0.35 to 1.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>880<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pneumonia</p> <p>Follow‐up: 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 6.12<br/> (0.73 to 51.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>880<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> assessed with SGRQ </p> <p>Mean change from baseline, scale 0‐100, low on the scale is better QoL<br/> Follow‐up: 12 weeks. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change from baseline in quality of life was</p> <p>–4.97 in one study</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.29 lower<br/> (3.01 lower to 0.42 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>779<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 1 study provided information on mean change from baseline in each group; the other study reported only differences between groups </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital admissions (all‐cause)<br/> Follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000<br/> (20 to 74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.96<br/> (0.49 to 1.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>880<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbations leading to intubation</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Physical activity measure<br/> (e.g. 6MWT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> <br/> 6MWT: 6‐Minute Walking Test; CI: confidence interval; COPD: chronic obstructive pulmonary disease; FF: fluticasone furoate; ICS: inhaled corticosteroids; LABA: long‐acting beta₂‐agonists; LAMA: long‐acting muscarinic antagonists; OR: odds ratio; QoL: quality of life; RCT: randomised controlled trial; SGRQ: St George's Respiratory Questionnaire; TIO: tiotropium; VI: vilanterol </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded for risk of bias by one level because both studies had unclear risk of bias for blinding and incomplete outcome data and one study did not provide information on methods of randomisation and concealment </p> <p><sup>b</sup>We downgraded for imprecision by two levels because very low number of events leads to wide 95% CIs, and the number of events was too low to reliably calculate optimal information size </p> <p><sup>c</sup>We downgraded for imprecision by two levels because the optimal information size criterion is not met and the 95% CI is wide including significant benefit and harm </p> <p><sup>d</sup>We downgraded for imprecision by two levels owing to very wide 95% CIs including significant benefit and harm </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012355-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012355-sec-0030"></div> <section id="CD012355-sec-0031"> <h3 class="title" id="CD012355-sec-0031">Description of the condition</h3> <p>Chronic obstructive pulmonary disease (COPD) is a disorder of the respiratory system that is characterised by significant mortality and morbidity worldwide. In 2012, COPD was the fourth leading cause of death in the world (<a href="./references#CD012355-bbs2-0037" title="GuerraS , SherrillDL , Kurzius‐SpencerM , VenkerC , HalonenM , QuanSF , et al. The course of persistent airflow limitation in subjects with and without asthma. Respiratory Medicine2008;102(10):1473‐82. ">Guerra 2008</a>). The World Health Organization (WHO) has reported more than three million deaths (<a href="./references#CD012355-bbs2-0070" title="World Health Organization. WHO Global Report: Preventing Chronic Diseases: A Vital Investment. Geneva: World Health Organization, 2005. www.who.int/chp/chronic_disease_report/en/ (accessed 1 January 2016). ">WHO 2005</a>), equivalent to 6% of deaths from all causes globally, and it is predicted that COPD will become the third leading cause of death worldwide by 2030 (<a href="./references#CD012355-bbs2-0053" title="MathersCD , LoncarD . Projections of global mortality and burden of disease from 2002 to 2030. PLoS Medicine2006;3(11):e442. ">Mathers 2006</a>). COPD is a chronic, progressive, and incurable condition that is usually caused by cigarette smoking. The underlying mechanism is associated with an enhanced chronic inflammatory response in the airways and within the lung to noxious particles or gases (<a href="./references#CD012355-bbs2-0035" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD 2018. http://goldcopd.org/wp‐content/uploads/2017/11/GOLD‐2018‐v6.0‐FINAL‐revised‐20‐Nov_WMS.pdf (accessed prior to 5 March 2018). ">GOLD 2018</a>). Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines describe COPD as a combination of obstructive bronchitis and emphysema (previously known as independent disease entities). The diagnosis of COPD is based on clinical manifestations, history of exposure to risk factors, and spirometry. <a href="./references#CD012355-bbs2-0035" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD 2018. http://goldcopd.org/wp‐content/uploads/2017/11/GOLD‐2018‐v6.0‐FINAL‐revised‐20‐Nov_WMS.pdf (accessed prior to 5 March 2018). ">GOLD 2018</a> decided to include individual patient symptoms as assessed by questionnaires such as the COPD Assessment Test (CAT) and the modified MRC Dyspnoea Scale (mMRC). Spirometry, which is required to establish a diagnosis of COPD, measures airflow limitation by post‐bronchodilator forced expiratory volume in one second (FEV₁)/forced vital capacity (FVC) ≤ 0.7 (independent of reference values) (<a href="./references#CD012355-bbs2-0035" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD 2018. http://goldcopd.org/wp‐content/uploads/2017/11/GOLD‐2018‐v6.0‐FINAL‐revised‐20‐Nov_WMS.pdf (accessed prior to 5 March 2018). ">GOLD 2018</a>). On the basis of symptoms and risks of exacerbation, patients are divided into four groups (A, B, C, and D). Patients in GOLD C or D categories may be at greater risk for hospital admission and death (<a href="./references#CD012355-bbs2-0035" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD 2018. http://goldcopd.org/wp‐content/uploads/2017/11/GOLD‐2018‐v6.0‐FINAL‐revised‐20‐Nov_WMS.pdf (accessed prior to 5 March 2018). ">GOLD 2018</a>). </p> </section> <section id="CD012355-sec-0032"> <h3 class="title" id="CD012355-sec-0032">Description of the intervention</h3> <p>The efficacy of COPD pharmacological management is rated by spirometry (FEV₁) and by an individualised assessment of disease course, which includes reduction in current symptoms and in future risks of exacerbation (<a href="./references#CD012355-bbs2-0035" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD 2018. http://goldcopd.org/wp‐content/uploads/2017/11/GOLD‐2018‐v6.0‐FINAL‐revised‐20‐Nov_WMS.pdf (accessed prior to 5 March 2018). ">GOLD 2018</a>). None of the medications available for COPD have been shown to modify the long‐term decline in lung function in a significant way (<a href="./references#CD012355-bbs2-0022" title="AnthonisenNR , ConnettJE , KileyJP , AltoseMD , BaileyWC , BuistAS , et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA1994;272(19):1497‐505. ">Anthonisen 1994</a>; <a href="./references#CD012355-bbs2-0025" title="BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA , MaslenTK . Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ2000;320(7245):1297‐303. ">Burge 2000</a>; <a href="./references#CD012355-bbs2-0035" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD 2018. http://goldcopd.org/wp‐content/uploads/2017/11/GOLD‐2018‐v6.0‐FINAL‐revised‐20‐Nov_WMS.pdf (accessed prior to 5 March 2018). ">GOLD 2018</a>; <a href="./references#CD012355-bbs2-0058" title="PauwelsRA , LöfdahlCG , LaitinenLA , SchoutenJP , PostmaDS , PrideNB , et al. Long‐term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. New England Journal of Medicine1999;340(25):1948‐53. ">Pauwels 1999</a>; <a href="./references#CD012355-bbs2-0065" title="VestboJ , SørensenT , LangeP , BrixA , TorreP , ViskumK . Long‐term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet1999;353(9167):1819‐23. ">Vestbo 1999</a>). Bronchodilators are used as first‐line medication for control of breathlessness. For group A patients, a short‐acting beta₂‐agonist (SABA) or a short‐acting anticholinergic agent (SAMA) may be recommended as first‐choice treatment (<a href="./references#CD012355-bbs2-0035" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD 2018. http://goldcopd.org/wp‐content/uploads/2017/11/GOLD‐2018‐v6.0‐FINAL‐revised‐20‐Nov_WMS.pdf (accessed prior to 5 March 2018). ">GOLD 2018</a>). In the case of persistent and worsening breathlessness (group B), long‐acting bronchodilators are used. Long‐acting beta₂‐agonists (LABA) are more effective than long‐acting anticholinergic agents (LAMA) if symptoms and health‐related quality of life are considered the primary outcomes, whereas use of LAMA is preferable among those with frequent exacerbations (<a href="./references#CD012355-bbs2-0028" title="CazzolaM , PageC . Long‐acting bronchodilators in COPD: where are we now and where are we going?. Breathe2014;10:110‐20. ">Cazzola 2014</a>). The choice of LABA or LAMA is dependent on patients' perception of symptom relief; for those with severe breathlessness, the alternative treatment is a combination of LAMA and LABA. Anti‐inflammatory interventions using oral corticosteroids should be restricted for the management of COPD exacerbations (<a href="./references#CD012355-bbs2-0035" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD 2018. http://goldcopd.org/wp‐content/uploads/2017/11/GOLD‐2018‐v6.0‐FINAL‐revised‐20‐Nov_WMS.pdf (accessed prior to 5 March 2018). ">GOLD 2018</a>). Inhaled corticosteroids (ICS) can be considered if the risk of recurrent exacerbations is high. <a href="./references#CD012355-bbs2-0035" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD 2018. http://goldcopd.org/wp‐content/uploads/2017/11/GOLD‐2018‐v6.0‐FINAL‐revised‐20‐Nov_WMS.pdf (accessed prior to 5 March 2018). ">GOLD 2018</a> recommends a combination of ICS and either LABA or LAMA for patients within the GOLD C category (<a href="./references#CD012355-bbs2-0023" title="BarrRG , BourbeauJ , CamargoCA , RamFS . Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD002876.pub2] ">Barr 2005</a>; <a href="./references#CD012355-bbs2-0026" title="CalverleyPM , BoonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. ">Calverley 2003</a>; <a href="./references#CD012355-bbs2-0027" title="CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. ">Calverley 2007</a>; <a href="./references#CD012355-bbs2-0057" title="NiewoehnerDE , RiceK , CoteC , PaulsonD , CooperJAJr , KorduckiL , et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once‐daily inhaled anticholinergic bronchodilator: a randomized trial. Annals of Internal Medicine2005;143(5):317‐26. ">Niewoehner 2005</a>; <a href="./references#CD012355-bbs2-0062" title="SpencerS , KarnerC , CatesCJ , EvansDJ . Inhaled corticosteroids versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2011, Issue 10. [DOI: 10.1002/14651858.CD007033.pub3] ">Spencer 2011</a>). The combination of two long‐acting bronchodilators or the combination of ICS and LAMA can be used as an alternative choice (<a href="./references#CD012355-bbs2-0035" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD 2018. http://goldcopd.org/wp‐content/uploads/2017/11/GOLD‐2018‐v6.0‐FINAL‐revised‐20‐Nov_WMS.pdf (accessed prior to 5 March 2018). ">GOLD 2018</a>). For group D patients, treatment recommendations include a combination of ICS plus LABA or LAMA or a combination of all three classes of drugs together; however, this guidance is based mostly on the findings of short‐term studies (<a href="./references#CD012355-bbs2-0035" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD 2018. http://goldcopd.org/wp‐content/uploads/2017/11/GOLD‐2018‐v6.0‐FINAL‐revised‐20‐Nov_WMS.pdf (accessed prior to 5 March 2018). ">GOLD 2018</a>). </p> </section> <section id="CD012355-sec-0033"> <h3 class="title" id="CD012355-sec-0033">How the intervention might work</h3> <p>Inhaled LABA, such as salmeterol or formoterol, improve FEV₁ and lead to a better health status and fewer exacerbations compared with placebo or short‐acting bronchodilators (<a href="./references#CD012355-bbs2-0063" title="StockleyRA , ChopraN , RiceL . Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax2006;61(2):122‐8. ">Stockley 2006</a>). LABA with a 24‐hour duration of action, such as indacaterol, vilanterol, and olodaterol, provide sustained bronchodilation compared with twice‐daily dosing with either salmeterol or formoterol, together with some reduction in use of rescue therapy or intensity of breathlessness, or both (<a href="./references#CD012355-bbs2-0032" title="DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65(6):473‐9. ">Dahl 2010</a>; <a href="./references#CD012355-bbs2-0048" title="KornS , KerwinE , AtisS , AmosC , OwenR , LassenC . Indacaterol once‐daily provides superior efficacy to salmeterol twice‐daily in COPD: a 12 month study. Respiratory Medicine2011;105(5):719‐26. ">Korn 2011</a>). </p> <p>Results of the Prevention of Exacerbations with Tiotropium (POET) in COPD study indicate that in patients with moderate to very severe COPD, LAMA (tiotropium) were significantly more effective than LABA (salmeterol) in preventing exacerbations (<a href="./references#CD012355-bbs2-0066" title="VogelmeierC , HedererB , GlaabT , SchmidtH , Rutten van MölkenMP , BeehKM , et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. New England Journal of Medicine2011;364(12):1093‐103. ">Vogelmeier 2011</a>). <a href="./references#CD012355-bbs2-0034" title="DecramerML , ChapmanKR , DahlR , FrithP , DavouassouxG , FritscherC , et al. Once‐daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomized blinded, parallel‐group study. Lancet Respiratory Medicine2013;1(7):524‐33. ">Decramer 2013</a> observed similar results when comparing once‐daily LABA (indacaterol) versus tiotropium. The new LAMA agents (aclidinium, glycopyrronium, and umeclidinium) have at least comparable efficacy to tiotropium, and choice of treatment depends on physician and patient preference (<a href="./references#CD012355-bbs2-0042" title="IsmailaAS , HuismanEL , PunekarYS , KarabisA . Comparative efficacy of long‐acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta‐analysis. International Journal of Chronic Obstructive Pulmonary Disease2015;10:2495‐517. ">Ismaila 2015</a>). </p> <p>ICS have been used in COPD treatment for many years. The benefits of ICS treatment for patients with COPD may be similar to those of LABA, but long‐term monotherapy with ICS is not recommended. Consistent evidence indicates that long‐term use of fluticasone‐based ICS is associated with increased risk of pneumonia (<a href="./references#CD012355-bbs2-0027" title="CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. ">Calverley 2007</a>; <a href="./references#CD012355-bbs2-0067" title="WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AsariZ , StockleyRA . The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. American Journal of Respiratory and Critical Care Medicine2008;177(1):19‐26. ">Wedzicha 2008</a>), as well as pulmonary tuberculosis (<a href="./references#CD012355-bbs2-0046" title="KimJH , ParkJS , KimKH , JeongHC , KimEK , LeeJH . Inhaled corticosteroid is associated with an increased risk of TB in patients with COPD. Chest2013;143(4):1018‐24. ">Kim 2013</a>). Compared to placebo, ICS such as fluticasone propionate and budesonide as monotherapy reduce exacerbations by up to 20% and in combination with LABA by up to 30%. The combination of ICS and LABA is better than its components and placebo in improving lung function and health status as well (<a href="./references#CD012355-bbs2-0026" title="CalverleyPM , BoonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. ">Calverley 2003</a>; <a href="./references#CD012355-bbs2-0027" title="CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. ">Calverley 2007</a>). When compared with once‐daily tiotropium, the twice‐daily combination of salmeterol and fluticasone propionate (SFC) had a similar effect on the overall exacerbation rate (<a href="./references#CD012355-bbs2-0067" title="WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AsariZ , StockleyRA . The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. American Journal of Respiratory and Critical Care Medicine2008;177(1):19‐26. ">Wedzicha 2008</a>). The only approved once‐daily fixed combination of vilanterol and fluticasone furoate produced greater improvement in lung function than its components separately and is as effective as the other twice‐daily administered combinations of ICS and LABA in preventing exacerbations (<a href="./references#CD012355-bbs2-0052" title="MartinezFJ , CalverleyPM , GoerhingUM , BroseM , FabbriLM , RabeKF . Effect of roflumilast on exacerbation in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomized controlled trial. Lancet2015;385(9971):857‐66. ">Martinez 2015</a>; <a href="./references#CD012355-bbs2-0064" title="StynesG , SvedsaterH , WexJ , LettisS , LeatherD , CastelnuovoE , et al. Once‐daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD – mixed treatment comparison of clinical efficacy. Respiratory Research2015;16:25. ">Stynes 2015</a>). On the other hand, the Effect of Indacaterol‐Glucopyrronium Versus Fluticasone‐Salmeterol on COPD Exacerbations (FLAME) study confirmed that once‐daily indacaterol‐glycopyrronium is more effective than twice‐daily salmeterol‐fluticasone in preventing exacerbations among patients with a history of exacerbations during the previous year (<a href="./references#CD012355-bbs2-0068" title="WedzichaJA , BanerjiD , ChapmanKR , VestboJ , RocheN , AyersRT , et al. Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD. New England Journal of Medicine2016;374(23):2222‐34. [DOI: 10.1056/NEJMoa1516385] ">Wedzicha 2016</a>). Finally, recently published results of the Inpatient Mortality Prediction Algorithm Clinical Trial (IMPACT) trial reveal that triple therapy with fluticasone furoate, umeclidinium, and vilanterol in a single inhaler resulted in lower rates of moderate to severe COPD exacerbation than were seen with fluticasone furoate‐vilanterol or umeclidinium‐vilanterol in the same population (<a href="./references#CD012355-bbs2-0049" title="LipsonDA , BarnhartF , BrealeyN , BrooksJ , CrinerGJ , DayNC , et al. Once‐daily single‐inhaler triple versus dual therapy in patients with COPD. New England Journal of Medicine2018;3(378(18)):1671‐80. [DOI: 10.1056/NEJMoa1713901] ">Lipson 2018</a>). </p> </section> <section id="CD012355-sec-0034"> <h3 class="title" id="CD012355-sec-0034">Why it is important to do this review</h3> <p>This Cochrane Review will be the first to directly compare once‐daily ICS/LABA combined in one inhaler versus inhaled LAMA. Patients with COPD, as others with chronic diseases, experience problems in adhering to treatment (<a href="./references#CD012355-bbs2-0059" title="RandCS , NidesM , CowlesMK , WiseRA , ConnettJ . Long‐term metered‐dose inhaler adherence in a clinical trial. The Lung Health Study Research Group. American Journal of Respiratory and Critical Care Medicine1995;152(2):580‐8. ">Rand 1995</a>). Even though it is not a single factor, dosing frequency has been suggested to influence therapy (<a href="./references#CD012355-bbs2-0024" title="BourbeauJ , BartlettSJ . Patient adherence in COPD. Thorax2008;63(9):831‐8. ">Bourbeau 2008</a>; <a href="./references#CD012355-bbs2-0029" title="CharlesMS , BlanchetteCM , SilverH , LavalleeD , DalalAA , MapelD . Adherence to controller therapy for chronic obstructive pulmonary disease: a review. Current Medical Research and Opinion2010;26(10):2421–9. ">Charles 2010</a>). It seems that once‐daily dosing offers greater convenience to patients and may markedly influence their adherence to treatment. Previous reviews have focused on twice‐daily ICS/LABA inhalers and have covered the following comparisons: ICS/LABA combined inhalers versus ICS alone (<a href="./references#CD012355-bbs2-0056" title="NanniniLJ , PooleP , MilanSJ , KestertonA . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD006826.pub2] ">Nannini 2013</a>); ICS/LABA combined inhalers in addition to tiotropium versus tiotropium (<a href="./references#CD012355-bbs2-0069" title="WelshEJ , CatesCJ , PooleP . Combination inhaled steroid and long‐acting beta2‐agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD007891.pub3] ">Welsh 2013</a>), or combination alone (<a href="./references#CD012355-bbs2-0043" title="KarnerC , CatesCJ . Combination inhaled steroid and long‐acting beta2‐agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD008532.pub2] ">Karner 2011</a>); and ICS/LABA combined inhalers versus long‐acting beta₂‐agonists (<a href="./references#CD012355-bbs2-0055" title="NanniniLJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD006829.pub2] ">Nannini 2012</a>). One review performed a network meta‐analysis to compare LABA, LAMA, ICS, and ICS/LABA (<a href="./references#CD012355-bbs2-0044" title="KewKM , DiasS , CatesCJ . Long‐acting inhaled therapy (beta‐agonists, anticholinergics and steroids) for COPD: a network meta‐analysis. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD010844.pub2] ">Kew 2014</a>). None of these systematic reviews separated the different LAMA agents. Thus, our proposed systematic review is original and may be informative for COPD management. Moreover, this review will form part of a suite of reviews on various combinations of LAMA, LABA, and ICS for treatment of people with COPD. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012355-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012355-sec-0035"></div> <p>To compare a once‐daily combination of inhaled corticosteroid and long‐acting beta₂‐agonist inhalers (ICS/LABA) versus inhaled long‐acting muscarinic antagonists alone (LAMA) in people with chronic obstructive pulmonary disease (COPD). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012355-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012355-sec-0036"></div> <section id="CD012355-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012355-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) with a parallel or cross‐over group design of at least 12 weeks' duration. We included studies reported as full‐text articles, those published as abstracts only, and those with unpublished data. </p> </section> <section id="CD012355-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included adults (over 21 years old) with a diagnosis of COPD confirmed by an external set of criteria for this condition, such as those provided by the Global Initiative for chronic Obstructive Lung Disease (<a href="./references#CD012355-bbs2-0035" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD 2018. http://goldcopd.org/wp‐content/uploads/2017/11/GOLD‐2018‐v6.0‐FINAL‐revised‐20‐Nov_WMS.pdf (accessed prior to 5 March 2018). ">GOLD 2018</a>), the American Thoracic Society (ATS), the British Thoracic Society (BTS), or the Thoracic Society of Australia and New Zealand (TSANZ). </p> </section> <section id="CD012355-sec-0040"> <h4 class="title">Types of interventions</h4> <p>We included studies that compared participants randomised to receive any fixed combination of ICS/LABA once daily (in one inhaler) versus inhaled LAMA. </p> <p>We included participants with COPD who were taking co‐medications provided that the co‐medications were not part of the randomised treatment. </p> </section> <section id="CD012355-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD012355-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012355-list-0001"> <li> <p>Mortality, all‐cause</p> </li> <li> <p>Any COPD exacerbation that requires short‐burst oral corticosteroids or antibiotics, or both </p> </li> <li> <p>Pneumonia and other serious adverse events</p> </li> </ol> </p> </section> <section id="CD012355-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012355-list-0002"> <li> <p>Quality of life (measured with a validated scale for COPD, e.g. St George's Respiratory Questionnaire (SGRQ), Chronic Respiratory Disease Questionnaire) </p> </li> <li> <p>Hospital admissions, all‐cause and due to exacerbation</p> </li> <li> <p>Exacerbations leading to intubation</p> </li> <li> <p>Disease‐specific adverse events other than pneumonia</p> </li> <li> <p>Physical activity measure (e.g. results of six‐minute walk test (6MWT))</p> </li> <li> <p>Improvement in symptoms</p> </li> <li> <p>Use of rescue medications</p> </li> <li> <p>FEV₁</p> </li> </ol> </p> <p>We defined adverse events as serious and non‐serious according to International Conference on Harmonisation (ICH) Guideline definitions (<a href="./references#CD012355-bbs2-0041" title="International Conference on Harmonisation Expert Working Group. ICH harmonised tripartite guideline. Guideline for good clinical practice E6 (R1). www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf (accessed 7 January 2016). ">ICH‐GCP 1996</a>) (i.e. a serious fatal or non‐fatal adverse event is any event that leads to death, is life‐threatening, requires in‐patient hospitalisation or prolongs existing hospitalisation, or results in persistent or significant disability, and any important medical event that may have jeopardised the participant or requires intervention to prevent its effects). We defined any other adverse events as non‐serious. </p> <p>Reporting in a study one or more of the outcomes listed above was not an inclusion criterion for this review. </p> </section> </section> </section> <section id="CD012355-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012355-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We identified studies from the Cochrane Airways Trials Register, which is maintained by the Information Specialist for the Group. The Cochrane Airways Trials Register contains studies identified from several sources. </p> <p> <ol id="CD012355-list-0003"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL), through the Cochrane Register of Studies Online (crso.cochrane.org) (inception to date). </p> </li> <li> <p>Weekly searches of MEDLINE Ovid SP (1946 to date).</p> </li> <li> <p>Weekly searches of Embase Ovid SP (1974 to date).</p> </li> <li> <p>Monthly searches of PsycINFO Ovid SP (1967 to date).</p> </li> <li> <p>Monthly searches of the Cumulative Index to Nursing and Allied Health Literature (CINAHL) EBSCO (1937 to date). </p> </li> <li> <p>Monthly searches of the Allied and Complementary Medicine Database (AMED) EBSCO (all years to date). </p> </li> <li> <p>Handsearches of the proceedings of major respiratory conferences.</p> </li> </ol> </p> <p>Studies contained in the Trials Register are identified through search strategies based on the scope of Cochrane Airways. Details of these strategies, as well as a list of handsearched conference proceedings, are provided in <a href="./appendices#CD012355-sec-0100">Appendix 1</a>. See <a href="./appendices#CD012355-sec-0106">Appendix 2</a> for search terms used to identify studies for this review. </p> <p>We searched all databases from their inception to 14 May 2018, and we imposed no restriction on language of publication. </p> <p>We conducted a search of ClinicalTrials.gov (<a href="http://ClinicalTrials.gov" target="_blank">http://ClinicalTrials.gov</a>) and the WHO International Clinical Trials Registry Platform (<a href="http://who.int/ictrp/en/" target="_blank">http://who.int/ictrp/en/</a>) (20 September 2017). </p> <p>The Information Specialist of the Cochrane Airways Group suggested the search methods for identification of studies. </p> </section> <section id="CD012355-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all primary studies, review articles, guidelines, and Health Technology Assessment (HTA) reports identified through our searches. We contacted experts in the field and authors of identified studies to ask about unpublished data. We searched relevant manufacturers' websites for trial information and contacted them to request information about unpublished trials. Also we checked <a href="http://www.clinicaltrialresults.org/" target="_blank">http://www.clinicaltrialresults.org/</a> and websites of the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for unpublished data. </p> <p>We searched for errata or retractions from included studies published in full text on PubMed (<a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">www.ncbi.nlm.nih.gov/pubmed</a>), but we identified none. </p> </section> </section> <section id="CD012355-sec-0047"> <h3 class="title" id="CD012355-sec-0047">Data collection and analysis</h3> <section id="CD012355-sec-0048"> <h4 class="title">Selection of studies</h4> <p>We identified and excluded duplicates and collated multiple reports of the same study, so that each study, rather than each report, was the unit of interest in the review. We eliminated duplicate records of the same study using reference management software. Two pairs of review authors (MJ, AS, IGS, RN, MS, MMB) independently screened titles and abstracts for inclusion of all potential studies that we identified as a result of the search and coded them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. Each pair consisted of a content expert and an experienced methodologist. We resolved discrepancies by discussion and, if the two review authors could not resolve discrepancies, a third review author (MMB) acted as arbiter. We retrieved the full‐text study reports/publications of studies in the 'retrieve' category. Two groups of review authors (MJ, AS, IGS, RN, MS, MMB) independently screened the full‐text articles, identified studies for inclusion, and identified and recorded reasons for exclusion of ineligible studies. We resolved any disagreement through discussion or, if required, we consulted a third review author (MMB). We recorded the selection process in sufficient detail to complete a PRISMA flow diagram and a <a href="./references#CD012355-sec-0115" title="">Characteristics of excluded studies</a> table (<a href="./references#CD012355-bbs2-0054" title="MoherD , LiberatiA , TetzlaffJ , AltmanD . Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097] ">Moher 2009</a>). </p> </section> <section id="CD012355-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form to record study design, methods, population, intervention, outcomes, and results. If sufficient flexibility was available, we used Covidence software for data extraction (<a href="./references#CD012355-bbs2-0031" title="Veritas Health Innovation. Covidence. Version accessed prior to 5 March 2018. Melbourne, Australia: Veritas Health Innovation, 2016. ">Covidence 2016</a>); if not, we used a Microsoft Excel spreadsheet. We first tested a data collection form and made adjustments. Two pairs of review authors (MJ and RN; IGS and MS) extracted data from the included studies. We discussed disagreements, and a third review author (MMB) acted as arbiter if necessary. We extracted the following study characteristics. </p> <p> <ol id="CD012355-list-0004"> <li> <p>Methods: study design, total duration of study, details of any 'run‐in' period, number of study centres and locations, study settings, withdrawals, and date of study. </p> </li> <li> <p>Participants: N, mean age, age range, gender, severity of condition, diagnostic criteria, baseline lung function, smoking history, inclusion criteria, and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications, and excluded medications.</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported. </p> </li> <li> <p>Notes: funding for study, and notable conflicts of interest of study authors.</p> </li> </ol> </p> </section> <section id="CD012355-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two pairs of review authors (MJ and RN; IGS/MMB and MS) independently assessed the risk of bias for each included study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions,</i> and followed advice from this source document for each of the 'Risk of bias' domains (<a href="./references#CD012355-bbs2-0038" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We resolved disagreements by discussion or by involving another review author (MMB, AS). We assessed risk of bias according to the following domains. </p> <p> <ol id="CD012355-list-0005"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ol> </p> <p>We graded each potential source of bias as 'high', 'low', or 'unclear', and provided a quote from the study report together with a justification for our judgement in the 'Risk of bias' table. We summarised 'Risk of bias' judgements across different studies for each of the domains listed and separately for objective and subjective outcomes. </p> <p>When we considered treatment effects, we took into account the risk of bias for studies that contributed to that outcome. </p> <p>We classified studies as having low risk of bias if they were at low risk of bias in all domains. Otherwise, we classified studies as having high risk of bias. </p> <section id="CD012355-sec-0051"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>We conducted the review according to the published protocol and reported any deviations from it in the <a href="#CD012355-sec-0112">Differences between protocol and review</a> section of the systematic review. </p> </section> </section> <section id="CD012355-sec-0052"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as odds ratios (ORs) and continuous data as mean differences (MDs) if the scale used in the studies was the same, or as standardised mean differences (SMDs) if the scales used by study authors differed. We used adjusted results, estimated from the model with the highest number of covariates. When adjusted results were unavailable, we extracted both change from baseline and final score and used the former in the analysis (in the same meta‐analysis as the adjusted results). If the included studies reported results only as mean difference values with standard error or 95% confidence intervals (CIs), we pooled them using the generic inverse variance (GIV) method and the calculator available in Review Manager (RevMan) (<a href="./references#CD012355-bbs2-0060" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <p>If the numbers of participants within an event were unavailable, we analysed count data as time‐to‐event or rate ratios, as reported. We planned to pool rate ratios after transforming them to log values using the GIV option in RevMan (<a href="./references#CD012355-bbs2-0060" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <p>We undertook meta‐analyses only when this was meaningful (i.e. if treatments, participants, and the underlying clinical question were similar enough for pooling to make sense). </p> <p>We narratively described skewed data reported as medians and interquartile ranges.</p> <p>When a single trial reported multiple trial arms, we planned to include only the relevant trial arms. If we had identified a trial with two relevant intervention arms that we combined in a single meta‐analysis, we planned to halve the control group to avoid double‐counting. </p> <p>We used the end of the study as a measurement point for all included studies.</p> </section> <section id="CD012355-sec-0053"> <h4 class="title">Unit of analysis issues</h4> <p>In the case of dichotomous data, the unit of analysis was the participant. In the case of included studies using count data, we analysed them as rate ratios or time‐to‐event data. In the case of included studies in which rate ratios were reported, we used these values in the analysis. We did not identify any cross‐over trials. </p> </section> <section id="CD012355-sec-0054"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators to verify and obtain missing data such as key study characteristics and numerical outcome data; however we received no response from the study authors. When we did not consider the data to be missing at random, we planned to analyse them as treatment failures and to test this approach in a sensitivity analysis. </p> </section> <section id="CD012355-sec-0055"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the ChI² test and the I² statistic to measure heterogeneity among the studies in each analysis. We did not identify substantial heterogeneity (as defined as a rough estimate in the Cochrane Handbook: I² &gt; 50%) and thus did not explore possible causes with our prespecified subgroup analysis (<a href="./references#CD012355-bbs2-0038" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>).  </p> </section> <section id="CD012355-sec-0056"> <h4 class="title">Assessment of reporting biases</h4> <p>To minimise reporting bias, we planned to search multiple sources and to create and examine a funnel plot to explore possible small‐study and publication biases, but we included only two studies; therefore this was not possible. </p> </section> <section id="CD012355-sec-0057"> <h4 class="title">Data synthesis</h4> <p>We used a random‐effects model and planned to perform a sensitivity analysis with a fixed‐effect model. If, owing to heterogeneity, pooling of data was not possible, we summarised the findings using tables, figures, and text. If results of a single study are presented on a forest plot, then a fixed‐effect model is displayed. </p> <section id="CD012355-sec-0058"> <h5 class="title">'Summary of findings' table</h5> <p>We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it relates to studies that contribute data to the meta‐analyses for prespecified outcomes. We used methods and recommendations described in Sections 8.6 ('Presentation of assessments of risk of bias') and 11.5 ('Summary of findings' tables) of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012355-bbs2-0038" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), and we used GRADEpro Guideline Development Tool (GDT) software (<a href="./references#CD012355-bbs2-0036" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed prior to 5 March 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT</a>). We justified all decisions to downgrade or upgrade the quality of the evidence by using footnotes, and we made comments to aid the reader's understanding of the review when necessary. We included the following outcomes in the 'Summary of findings' table: mortality, any COPD exacerbation, pneumonia, hospital admission, COPD exacerbation leading to intubation, quality of life, and physical fitness. </p> </section> </section> <section id="CD012355-sec-0059"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Comparisons of treatment effects might be influenced by patient‐related and disease‐ or management‐associated modifiers, such as patient age or gender (<a href="./references#CD012355-bbs2-0050" title="ManninoDM , HomaDM , AkinbamiLJ , FordES , ReddSC . Chronic obstructive pulmonary disease surveillance United States, 1971‐2000. Respiratory Care2002;47(10):1184‐99. ">Mannino 2002</a>); smoking status (<a href="./references#CD012355-bbs2-0047" title="KohansalR , Martinez‐CamblorP , AgustíA , BuistAS , ManninoDM , SorianoJB . The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. American Journal of Respiratory and Critical Care Medicine2009;180(1):3‐10. ">Kohansal 2009</a>); co‐morbidities (cardiovascular, metabolic, etc.) (<a href="./references#CD012355-bbs2-0020" title="AgustiA , CalverleyPM , CelliB , CoxsonHO , EdwardsLD , LomasDA , et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respiratory Research2010;11:122. ">Agusti 2010</a>; <a href="./references#CD012355-bbs2-0039" title="HolguinF , FolchE , ReddSC , ManninoDM . Comorbidity and mortality in COPD‐related hospitalizations in the United States, 1979 to 2001. Chest2005;128(4):2005‐11. ">Holguin 2005</a>; <a href="./references#CD012355-bbs2-0051" title="ManninoDM , ThornD , SwensenA , HolguinF . Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. European Respiratory Journal2008;32(4):962‐9. ">Mannino 2008</a>); severity of airflow limitation (FEV₁) (<a href="./references#CD012355-bbs2-0033" title="DecramerM , CelliB , KestenS , LystigT , MehraS , TashkinDP . Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet2009;374(9696):1171‐8. ">Decramer 2009</a>; <a href="./references#CD012355-bbs2-0040" title="HurstJR , VestboJ , AnzuetoA , LocantoreN , MüllerovaH , Tal‐SingerR , et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. New England Journal of Medicine2010;363(12):1128‐38. ">Hurst 2010</a>); number of exacerbations in the prior 12 months (≤ 1 vs ≥ 2) (<a href="./references#CD012355-bbs2-0040" title="HurstJR , VestboJ , AnzuetoA , LocantoreN , MüllerovaH , Tal‐SingerR , et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. New England Journal of Medicine2010;363(12):1128‐38. ">Hurst 2010</a>); and type, dose, and delivery mode of studied, concomitant, and previous COPD medications (<a href="./references#CD012355-bbs2-0021" title="Al‐ShowairRA , TarsinWY , AssiKH , PearsonSB , ChrystynH . Can all patients with COPD use the correct inhalation flow with all inhalers and does training help?. Respiratory Medicine2007;101(11):2395‐401. ">Al‐Showair 2009</a>; <a href="./references#CD012355-bbs2-0030" title="ChrystynH , MulleyBA , PeakeMD . Dose response relation to oral theophylline in severe chronic obstructive airways disease. BMJ1988;297(662):1506‐10. ">Chrystyn 1988</a>; <a href="./references#CD012355-bbs2-0045" title="KimCS , KangTC . Comparative measurement of lung deposition of inhaled fine particles in normal subjects and patients with obstructive airway disease. American Journal of Respiratory and Critical Care Medicine1997;155(3):899‐905. ">Kim 1997</a>). However, those data were not available at the study level.<br/> <br/> We planned to analyse studies within the following a priori subgroups, using the formal test for subgroup interactions in Review Manager (RevMan) (<a href="./references#CD012355-bbs2-0060" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <p> <ol id="CD012355-list-0006"> <li> <p>Type and dose (mean or defined by primary studies protocols) of LABA.</p> </li> <li> <p>Type and dose (mean or defined by protocols) of LAMA.</p> </li> <li> <p>Type and dose (mean or defined by protocols) of ICS used.</p> </li> <li> <p>Number of exacerbations in prior 12 months (mean at baseline or according to inclusion criteria: ≤ 1 vs ≥ 2). </p> </li> <li> <p>Severity of airflow limitation (mean at baseline or according to inclusion criteria: FEV₁ &gt; 80% vs 50 to 80% vs &lt; 50% predicted). </p> </li> <li> <p>Prior therapy: inhaled ICS + LABA; inhaled LAMA (dichotomised as yes/no according to inclusion criteria). </p> </li> <li> <p>Concomitant medication: theophylline (dichotomised as yes/no according to inclusion criteria). </p> </li> <li> <p>Smoking status (current smokers dichotomised as yes/no according to inclusion criteria).</p> </li> <li> <p>Co‐morbidity (cardiac, vascular, metabolic (diabetes), etc.; dichotomised as yes/no according to inclusion criteria). </p> </li> <li> <p>Study duration (less than six months, ≥ six months).</p> </li> <li> <p>Open and double‐blind trial design.</p> </li> </ol> </p> <p>However, owing to lack of required data, we did not carry out these analyses.</p> </section> <section id="CD012355-sec-0060"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses with regard to missing data (best‐best; worst‐worst, and risk of bias low and high). Again, the small number of studies and the paucity of data precluded these analyses. Because events in cases of mortality and pneumonia were rare, we conducted additional post hoc sensitivity analysis using the Peto odds ratio. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012355-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012355-sec-0061"></div> <section id="CD012355-sec-0062"> <h3 class="title">Description of studies</h3> <section id="CD012355-sec-0063"> <h4 class="title">Results of the search</h4> <p>We performed our searches on 14 May 2018 and identified 475 records after removal of duplicates.See <a href="#CD012355-fig-0001">Figure 1</a> for an overview of literature search results, their assessment, and inclusion and exclusion of studies in the review. We have reported reasons for exclusions under <a href="./references#CD012355-sec-0115" title="">Characteristics of excluded studies</a>. Finally we included two studies that fulfil the criteria of our review (<a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a>, <a href="./references#CD012355-bbs2-0002" title="PepinJL , CockcroftJR , MidwinterD , SharmaS , RubinDB , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest2014;146(6):1521‐30. RubinDB , PepinJ‐L , CockcroftJR , MidwinterD , SharmaS , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187(Meeting Abstracts):A6027. ">Pepin 2014</a>). In addition, we identified one ongoing trial (<a href="./references#CD012355-bbs2-0019" title="Shanghai Pulmonary Hospital. Comparisons of Inhaled LAMA or ICS+LABA for COPD With Bronchiectasis. https://clinicaltrials.gov/ct2/show/NCT02546297. ">NCT02546297</a>). </p> <div class="figure" id="CD012355-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012355-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012355-sec-0064"> <h4 class="title">Included studies</h4> <p>The two included studies were described as randomised controlled trials (RCTs) and as double‐blind studies (<a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a>, <a href="./references#CD012355-bbs2-0002" title="PepinJL , CockcroftJR , MidwinterD , SharmaS , RubinDB , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest2014;146(6):1521‐30. RubinDB , PepinJ‐L , CockcroftJR , MidwinterD , SharmaS , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187(Meeting Abstracts):A6027. ">Pepin 2014</a>). We present detailed information on the methods used in each study under <a href="./references#CD012355-sec-0114" title="">Characteristics of included studies</a>. </p> <section id="CD012355-sec-0065"> <h5 class="title">Participants</h5> <p>Both studies recruited in total 880 participants (50% were men) aged ≥ 40 years (mean age, 63 years) with a diagnosis of COPD confirmed by an external set of criteria for this condition and a history of ≥ 10 pack‐years of smoking, with partially reversible or non‐reversible airflow limitation and mean percent predicted (%pred) FEV₁ of 45.4. In each study, follow‐up lasted 12 weeks. </p> <p>In both studies, a high proportion of participants had cardiovascular co‐morbidities; the most common were hypertension (75% and 84%), hypercholesterolaemia (41% and 44%), and coronary artery disease (32% and 44%). </p> </section> <section id="CD012355-sec-0066"> <h5 class="title">Location and setting</h5> <p>The included studies were co‐ordinated in Germany (at the Lung Clinic in the Medical University of Göttingen, per <a href="./references#CD012355-bbs2-0002" title="PepinJL , CockcroftJR , MidwinterD , SharmaS , RubinDB , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest2014;146(6):1521‐30. RubinDB , PepinJ‐L , CockcroftJR , MidwinterD , SharmaS , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187(Meeting Abstracts):A6027. ">Pepin 2014</a>) and in the USA (at Kootenai Health, Coeur d'Alene, Idaho, per <a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a>). </p> <p>Patients were recruited at 102 medical centres (outpatient clinics) in 11 countries (Argentina, Canada, Czech Republic, France, Germany, Italy, Norway, Poland, Romania Russian Federation, Ukraine, and the USA) (<a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a><a href="./references#CD012355-bbs2-0002" title="PepinJL , CockcroftJR , MidwinterD , SharmaS , RubinDB , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest2014;146(6):1521‐30. RubinDB , PepinJ‐L , CockcroftJR , MidwinterD , SharmaS , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187(Meeting Abstracts):A6027. ">Pepin 2014</a>). </p> </section> <section id="CD012355-sec-0067"> <h5 class="title">Interventions</h5> <p>In the included studies, the combination inhaled ICS/LABA was fluticasone and vilanterol 100/25 mcg once daily in <a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a> and <a href="./references#CD012355-bbs2-0002" title="PepinJL , CockcroftJR , MidwinterD , SharmaS , RubinDB , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest2014;146(6):1521‐30. RubinDB , PepinJ‐L , CockcroftJR , MidwinterD , SharmaS , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187(Meeting Abstracts):A6027. ">Pepin 2014</a>, respectively, versus 18 mcg tiotropium. Each participant was instructed to self‐administer the blinded study drug. Dosage of the combined preparation and of the separate medications remained stable throughout the studies. Concomitant therapy permitted was as‐needed short‐acting beta₂‐agonist (salbutamol) or oral steroids or antibiotics, or both, in the case of exacerbations. </p> </section> <section id="CD012355-sec-0068"> <h5 class="title">Outcomes</h5> <p>Both studies reported any COPD exacerbation that required short‐burst oral corticosteroids or antibiotics or hospitalisation. Both studies reported mortality, but only as fatal adverse events. Each study measured and reported pneumonia and other serious adverse events. Both studies reported lung function as FEV₁, and one study reported change from baseline in 24 hours weight mean FEV₁ at week 12 as a primary endpoint (<a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a>). Both studies reported quality of life assessment by St George's Respiratory Questionnaire (SGRQ)‐COPD, as well as improvement in symptoms assessment by the COPD Assesment Test (CAT). Only <a href="./references#CD012355-bbs2-0002" title="PepinJL , CockcroftJR , MidwinterD , SharmaS , RubinDB , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest2014;146(6):1521‐30. RubinDB , PepinJ‐L , CockcroftJR , MidwinterD , SharmaS , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187(Meeting Abstracts):A6027. ">Pepin 2014</a> used the EuroQoL Goup Quality of Life Questionnaire based on five dimensions (EQ‐5D). Studies also reported vital signs (blood pressure and pulse rate), spirometry parameters, and clinical laboratory tests (hematology and chemistry). The primary outcome in one study was mean change from baseline (BL) in aortic pulse wave velocity (aPWV) at the end of the 12‐week treatment period (day 84) (<a href="./references#CD012355-bbs2-0002" title="PepinJL , CockcroftJR , MidwinterD , SharmaS , RubinDB , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest2014;146(6):1521‐30. RubinDB , PepinJ‐L , CockcroftJR , MidwinterD , SharmaS , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187(Meeting Abstracts):A6027. ">Pepin 2014</a>). </p> </section> </section> <section id="CD012355-sec-0069"> <h4 class="title">Excluded studies</h4> <p>We provide reasons for exclusion under <a href="./references#CD012355-sec-0115" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD012355-sec-0070"> <h3 class="title">Risk of bias in included studies</h3> <p>We graded each potential source of bias as high, low, or unclear and provided an explanation from the study report together with a justification for our judgement in the 'Risk of bias' table. We present details for each study under <a href="./references#CD012355-sec-0114" title="">Characteristics of included studies</a>. <a href="#CD012355-fig-0002">Figure 2</a> shows the overall risk of bias in each domain for studies in this review. Risk of bias by trial can be seen in <a href="#CD012355-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD012355-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012355-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD012355-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012355-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <p>Both included studies were published in full articles, and neither study was at low risk of bias in all domains (<a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a><a href="./references#CD012355-bbs2-0002" title="PepinJL , CockcroftJR , MidwinterD , SharmaS , RubinDB , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest2014;146(6):1521‐30. RubinDB , PepinJ‐L , CockcroftJR , MidwinterD , SharmaS , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187(Meeting Abstracts):A6027. ">Pepin 2014</a>). </p> <section id="CD012355-sec-0071"> <h4 class="title">Allocation</h4> <p>Both studies were randomised trials, and we gave neither study high risk ratings for either of the selection bias domains. One study described the method of randomisation, and thus we rated this study as having low risk of bias (<a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a>).<br/> <br/> One study described the method of allocation concealment (interactive voice response system), and we rated this study as having low risk of bias (<a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a>). The second study did not explicitly describe its methods; therefore we rated this study as having unclear risk of bias. </p> </section> <section id="CD012355-sec-0072"> <h4 class="title">Blinding</h4> <p>Both studies were double‐blind, which was understood to pertain to at least participants and personnel; therefore we gave both studies a low risk rating for performance and detection bias for objective outcomes. However, for both trials, we rated the risk of bias for subjective outcomes as unclear in performance and detection domains, as capsules in one of the groups had trade markings, but it was not clear if participants noted the difference. </p> </section> <section id="CD012355-sec-0073"> <h4 class="title">Incomplete outcome data</h4> <p>Both studies described withdrawals, but not all participants were included in the analyses of secondary outcomes, and it was not clear how studies dealt with missing data for those outcomes. We therefore rated both trials as having unclear risk of bias in the incomplete outcome data domain. </p> </section> <section id="CD012355-sec-0074"> <h4 class="title">Selective reporting</h4> <p>Both trials could be linked to a prospectively registered protocol for cross‐checking of reported outcomes (on clinicaltrials.gov). Both studies reported named outcomes well in published articles, and a subset had additionally posted results summaries on clinicaltrials.gov, warranting a low risk rating. </p> </section> <section id="CD012355-sec-0075"> <h4 class="title">Other potential sources of bias</h4> <p>Both studies did not report any important concerns about bias not addressed in the other domains in the tool. </p> </section> </section> <section id="CD012355-sec-0076"> <h3 class="title" id="CD012355-sec-0076">Effects of interventions</h3> <p>See: <a href="./full#CD012355-tbl-0001"><b>Summary of findings for the main comparison</b> Once‐daily ICS/LABA combined inhalers compared to once‐daily LAMA for people with chronic obstructive pulmonary disease</a> </p> <section id="CD012355-sec-0077"> <h4 class="title">Mortality</h4> <p>In both studies, death was reported only in patients receiving TIO (four participants). Overall, the main analysis did not demonstrate statistically significant differences in the number of deaths between fluticasone furoate (FF)/vilanterol (VI) and tiotropium (TIO) (OR 0.20, 95% CI 0.02 to 1.73; 880 participants; <a href="./references#CD012355-fig-0008" title="">Analysis 1.1</a>; <a href="#CD012355-fig-0004">Figure 4</a>). However, because events were so rare, we performed an additional sensitivity analysis using the Peto OR, which showed some benefit of FF/VI as compared with TIO (Peto OR 0.14, 95% CI 0.02 to 0.97; 880 participants; <a href="./references#CD012355-fig-0018" title="">Analysis 2.1</a>). </p> <div class="figure" id="CD012355-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), outcome: 1.1 Mortality all‐cause." data-id="CD012355-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), outcome: 1.1 Mortality all‐cause. </p> </div> </div> </div> <p>Mortality was not analysed as a primary outcome in the included studies.</p> </section> <section id="CD012355-sec-0078"> <h4 class="title">Any COPD exacerbation</h4> <p>Both studies did not provide a definition of COPD exacerbation, and both reported severe exacerbations (exacerbation leading to hospitalisation) as a safety endpoint. One study presented a definition of exacerbation history (<a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a>), which we accepted as the definition of COPD exacerbations during the study ("exacerbation requiring oral corticosteroid and/or antibiotic treatment and/or hospitalisation"). In <a href="./references#CD012355-bbs2-0002" title="PepinJL , CockcroftJR , MidwinterD , SharmaS , RubinDB , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest2014;146(6):1521‐30. RubinDB , PepinJ‐L , CockcroftJR , MidwinterD , SharmaS , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187(Meeting Abstracts):A6027. ">Pepin 2014</a>, data for COPD worsening or exacerbation were reported together and only as adverse events. We combined these two endpoints in a single analysis of exacerbations. The total number of people experiencing one or more exacerbations in both studies was 13 in the FF/VI group and 18 in the TIO group (OR 0.72, 95% Cl 0.35 to 1.50; 880 participants; <a href="./references#CD012355-fig-0009" title="">Analysis 1.2</a>; <a href="#CD012355-fig-0005">Figure 5</a>). None of the COPD exacerbations were fatal. </p> <div class="figure" id="CD012355-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), outcome: 1.2 Any COPD exacerbation that requires short‐burst oral corticosteroids or antibiotics, or both." data-id="CD012355-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), outcome: 1.2 Any COPD exacerbation that requires short‐burst oral corticosteroids or antibiotics, or both. </p> </div> </div> </div> </section> <section id="CD012355-sec-0079"> <h4 class="title">Pneumonia and other serious adverse events</h4> <p>Both studies observed pneumonia only in the FF/VI group, but the difference versus the TIO group was not statistically significant in the main analysis (OR 6.12, 95% Cl 0.73 to 51.24; 880 participants; <a href="./references#CD012355-fig-0010" title="">Analysis 1.3</a>; <a href="#CD012355-fig-0006">Figure 6</a>). However, because events were so rare, we performed an additional sensitivity analysis using the Peto OR, which showed increased risk of pneumonia in the FF/VI group as compared with the TIO group (Peto OR 7.56, 95% Cl 1.30 to 43.75; 880 participants; <a href="./references#CD012355-fig-0019" title="">Analysis 2.2</a>). </p> <div class="figure" id="CD012355-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Once daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists(TIO), outcome: 1.3 Pneumonia." data-id="CD012355-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Once daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists(TIO), outcome: 1.3 Pneumonia. </p> </div> </div> </div> <p>In total, studies reported five pneumonias, none of which were fatal. One study radiologically confirmed pneumonia and treated patients with antibiotics in each case (n = 3; <a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a>). Two of the three participants were hospitalised. In the other study, pneumonia was not defined but was reported as a serious adverse event (n = 2; <a href="./references#CD012355-bbs2-0002" title="PepinJL , CockcroftJR , MidwinterD , SharmaS , RubinDB , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest2014;146(6):1521‐30. RubinDB , PepinJ‐L , CockcroftJR , MidwinterD , SharmaS , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187(Meeting Abstracts):A6027. ">Pepin 2014</a>), and all participants with pneumonia were hospitalised. </p> <p>All studies evaluated serious adverse events (SAEs) at 12 weeks' observation. Researchers reported no significant differences in the number of SAEs between groups (OR 0.96, 95% Cl 0.50 to 1.83; 880 participants; <a href="./references#CD012355-fig-0011" title="">Analysis 1.4</a>; <a href="#CD012355-fig-0007">Figure 7</a>). We gathered data on other SAEs as reported according to <i>Medical Dictionary for Regulatory Activities (MedDRA)</i> terminology in <a href="#CD012355-tbl-0002">Table 1</a>. </p> <div class="figure" id="CD012355-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), outcome: 1.4 Total, serious adverse events." data-id="CD012355-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), outcome: 1.4 Total, serious adverse events. </p> </div> </div> </div> <div class="table" id="CD012355-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other serious adverse events</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Coveli 2015</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FF/VI, n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIO, n (%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Cardiac disorders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Cardio‐respiratory arrest</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/313 (0.64)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Acute myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/313 (0.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Cardiac failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/313 (0.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Cardiac failure congestive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/313 (0.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Infections and infestations</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Urinary tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/310 (0.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/313 (0.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Graft infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/313 (0.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Post‐procedural infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/310 (0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/313 (0.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Injury, poisoning, and procedural complications</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Alcohol poisoning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/313 (0.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Anaemia postoperative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/310 (0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/313 (0.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Cardiac procedure complication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/313 (0.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Patella fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/310 (0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/313 (0.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Metabolism and nutrition disorders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Dehydration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/313 (0.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Hypercholesterolaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/313 (0.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Neoplasms benign, malignant and unspecified (including cysts and polyps)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Pancreatic carcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/310 (0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/313 (0.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Nervous system disorders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Epilepsy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/313 (0.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Psychiatric disorders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Alcohol abuse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/313 (0.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/313 (0.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Vascular disorders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Blood pressure fluctuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/310 (0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/313 (0.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Leriche syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/313 (0.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Thrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/310 (0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/313 (0.00)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Pepin 2014</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FF/VI, n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIO, n (%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Gastrointestinal disorders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Acute abdomen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/127 (0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/130 (0.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Pancreatolithiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/127 (0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/130 (0.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>General disorders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/127 (0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/130 (0.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Hepatobiliary disorders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Bile duct obstruction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/127 (0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/130 (0.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Infections and infestations</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Peritonsillar abscess</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/127 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/130 (0.77)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Injury, poisoning, and procedural complications</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Multiple injuries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/127 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/130 (0.77)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Neoplasms benign, malignant, and unspecified (including cysts and polyps)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Bronchial carcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/127 (0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/130 (0.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Nervous system disorders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Altered state of consciousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/127 (0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/130 (0.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Respiratory, thoracic, and mediastinal disorders</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Pulmonary embolism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/127 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/130 (0.77)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Skin and subcutaneous tissue disorders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Skin ulcer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/127 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/130 (0.77)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>FF: fluticasone furoate; TIO: tiotropium; VI: vilanterol.</p> </div> </div> </section> <section id="CD012355-sec-0080"> <h4 class="title">Quality of life</h4> <p>Both included studies looked at changes in quality of life using the SGRQ, and both showed improvement in quality of life (with respect to all COPD‐specific (SGRQ‐C) components: symptoms, impacts, activity) in both groups (<a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a>, <a href="./references#CD012355-bbs2-0002" title="PepinJL , CockcroftJR , MidwinterD , SharmaS , RubinDB , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest2014;146(6):1521‐30. RubinDB , PepinJ‐L , CockcroftJR , MidwinterD , SharmaS , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187(Meeting Abstracts):A6027. ">Pepin 2014</a>). Lower scores indicate better quality of life. </p> <p>In <a href="./references#CD012355-bbs2-0002" title="PepinJL , CockcroftJR , MidwinterD , SharmaS , RubinDB , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest2014;146(6):1521‐30. RubinDB , PepinJ‐L , CockcroftJR , MidwinterD , SharmaS , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187(Meeting Abstracts):A6027. ">Pepin 2014</a>, data for SGRQ change after 12 weeks were available for each group, and <a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a> provided information about mean change differences between groups. Therefore, with Review Manager (RevMan) (<a href="./references#CD012355-bbs2-0060" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), we calculated the mean change difference between FF/VI and TIO groups at day 84 using data available in the e‐Appendix of <a href="./references#CD012355-bbs2-0002" title="PepinJL , CockcroftJR , MidwinterD , SharmaS , RubinDB , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest2014;146(6):1521‐30. RubinDB , PepinJ‐L , CockcroftJR , MidwinterD , SharmaS , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187(Meeting Abstracts):A6027. ">Pepin 2014</a>. </p> <p>The mean change difference between groups in total SGRQ was not significant (MD ‐1.29, 95% CI ‐3.01 to 0.42; 779 participants; <a href="./references#CD012355-fig-0012" title="">Analysis 1.5</a>). </p> <p><a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a> performed a responder analysis for the total SGRQ‐C score. Study authors reported that 48% and 42% of participants achieved the minimal clinically important difference (MCID) of ‐4 units after 12 weeks of treatment with FF/VI and TIO, respectively. Using percentages reported by authors and total numbers of participants, we calculated the number of responders in each group, which did not show significant differences between groups (OR 1.27, 95% Cl 0.93 to 1.74; 313 participants; <a href="./references#CD012355-fig-0013" title="">Analysis 1.6</a>). </p> </section> <section id="CD012355-sec-0081"> <h4 class="title">Hospital admissions: all‐cause and due to exacerbation</h4> <p>Studies included in this review did not explicitly report the number of participants hospitalised; therefore we assumed that the total number of SAEs was equivalent to the number of hospitalisations for any reason. Study data were available for comparison of the rate of hospitalisation due to a COPD exacerbation versus pneumonia (<a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a><a href="./references#CD012355-bbs2-0002" title="PepinJL , CockcroftJR , MidwinterD , SharmaS , RubinDB , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest2014;146(6):1521‐30. RubinDB , PepinJ‐L , CockcroftJR , MidwinterD , SharmaS , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187(Meeting Abstracts):A6027. ">Pepin 2014</a>). Those studies observed no significant differences in hospitalisation for any reason between FF/VI and TIO groups (OR 0.96, 95% CI 0.49 to 1.89; 880 participants; <a href="./references#CD012355-fig-0014" title="">Analysis 1.7</a>). </p> </section> <section id="CD012355-sec-0082"> <h4 class="title">Exacerbations leading to intubation</h4> <p>Included studies did not report this outcome.</p> </section> <section id="CD012355-sec-0083"> <h4 class="title">Disease‐specific adverse events other than pneumonia</h4> <p>Both studies, which enrolled 880 participants in total, reported adverse events related to COPD (<a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a><a href="./references#CD012355-bbs2-0002" title="PepinJL , CockcroftJR , MidwinterD , SharmaS , RubinDB , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest2014;146(6):1521‐30. RubinDB , PepinJ‐L , CockcroftJR , MidwinterD , SharmaS , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187(Meeting Abstracts):A6027. ">Pepin 2014</a>). Authors of both studies reported cardiovascular events (n = 35), lower respiratory tract infection excluding pneumonia (n = 8), local steroid effects (n = 31), bone disorders/fractures (n = 5), and ocular effects/glaucoma (n = 2). They reported no significant differences between treated groups (FF/VI vs TIO) for any of the analysed disease‐specific adverse events (<a href="./references#CD012355-fig-0015" title="">Analysis 1.8</a>). In addition, analysis of any adverse events (not including serious) showed no differences between two treatment groups (OR 0.99, 95% CI 0.62 to 1.57; 880 participants; <a href="./references#CD012355-fig-0015" title="">Analysis 1.8</a>). We gathered the data on other adverse events reported in <a href="#CD012355-tbl-0003">Table 2</a>. </p> <div class="table" id="CD012355-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Other adverse events</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Covelli 2015</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Pepin 2014</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FF/VI, n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIO, n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FF/VI, n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIO, n (%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total, other (not including serious) adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/310 (10.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32/313 (10.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/127 (6.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/130 (6.15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Infections and infestations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Nasopharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/310 (5.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/313 (4.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/127 (3.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/130 (3.08)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Nervous system disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/310 (5.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/313 (7.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/127 (2.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/130 (3.85)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>FF: fluticasone furoate; TIO: tiotropium; VI: vilanterol.</p> </div> </div> </section> <section id="CD012355-sec-0084"> <h4 class="title">Physical activity measure (e.g. results of six‐minute walk test (6MWT))</h4> <p>The included studies did not report this outcome.</p> </section> <section id="CD012355-sec-0085"> <h4 class="title">Improvement in symptoms</h4> <p>Both studies used the CAT score to assess severity of symptoms over the entire 12‐week treatment period. Lower scores indicate fewer symptoms. However, one study reported least squares mean change differences between groups (<a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a>), and the other study reported CAT values at 84 days (<a href="./references#CD012355-bbs2-0002" title="PepinJL , CockcroftJR , MidwinterD , SharmaS , RubinDB , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest2014;146(6):1521‐30. RubinDB , PepinJ‐L , CockcroftJR , MidwinterD , SharmaS , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187(Meeting Abstracts):A6027. ">Pepin 2014</a>). Because data were insufficient for pooling of results of both studies, we have presented them narratively. In <a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a>, least squares mean change differences between groups in total CAT score at 12 weeks was ‐0.4 (95% CI ‐1.3 to 0.5; 565 participants), and in <a href="./references#CD012355-bbs2-0002" title="PepinJL , CockcroftJR , MidwinterD , SharmaS , RubinDB , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest2014;146(6):1521‐30. RubinDB , PepinJ‐L , CockcroftJR , MidwinterD , SharmaS , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187(Meeting Abstracts):A6027. ">Pepin 2014</a>, the difference in CAT scores between FF/VI and TIO groups at 12 weeks was 0.6 (95% CI ‐1.31 to 2.51; 257 participants) (<a href="./references#CD012355-fig-0016" title="">Analysis 1.9</a>). On the basis of available data, we could calculate only mean change in both groups from baseline, which was ‐3 in the FF/VI group and ‐2.5 in the TIO group, with a difference of ‐0.5. </p> </section> <section id="CD012355-sec-0086"> <h4 class="title">Use of rescue medications</h4> <p>Analyses for mean weekly rescue medication use of albuterol/salmeterol over the 12‐week course of the study were available for only one study (<a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a>). Researchers reported a significant difference between groups (FF/VI vs TIO) in mean weekly use of SABA/LABA (‐0.37 inhalations, 95% CI −0.55 to −0.19; 565 participants) and in mean weekly percentage of rescue‐free days (9.1%, 95% CI 4.0 to 14.2; 565 participants). Albuterol use was measured as occasions used per day. </p> </section> <section id="CD012355-sec-0087"> <h4 class="title">FEV₁</h4> <p>Both studies measured change from baseline in trough FEV₁ at the end of the study (12 weeks). We have presented the results for 268 and 249 participants available for analysis in FF/VI and TIO groups in one study (<a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a>) and for 112 and 112 participants available for analysis in the second study (<a href="./references#CD012355-bbs2-0002" title="PepinJL , CockcroftJR , MidwinterD , SharmaS , RubinDB , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest2014;146(6):1521‐30. RubinDB , PepinJ‐L , CockcroftJR , MidwinterD , SharmaS , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187(Meeting Abstracts):A6027. ">Pepin 2014</a>). Because both studies reported least squares mean change difference with 95% CI, we calculated the standard error from available data and pooled mean differences. As a result, we found no significant differences between FF/VI and TIO groups (MD 0.01, 95% CI ‐0.02 to 0.04; 741 participants; <a href="./references#CD012355-fig-0017" title="">Analysis 1.10</a>). </p> <p>In addition, <a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a> presented dichotomous improvement for a change in FEV₁ ≥ 100 mL from baseline within four hours post dose on treatment day 1. An increase ≥ 100 mL was not met for 21% and 18% of participants receiving FF/VI and TIO, respectively; however the change from baseline ≥ 100 mL within five minutes was achieved by 36% of participants receiving FF/VI and by 23% of those receiving TIO. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012355-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012355-sec-0088"></div> <section id="CD012355-sec-0089"> <h3 class="title" id="CD012355-sec-0089">Summary of main results</h3> <p>We reviewed data from two randomised trials (880 participants) comparing efficacy and safety of a once‐daily combination of inhaled corticosteroid and long‐acting beta₂‐agonist (ICS/LABA) in one inhaler versus inhaled long‐acting muscarinic antagonist alone (LAMA) in patients with chronic obstructive pulmonary disease (COPD). In both studies, assessment of cardiovascular events was the main objective<i><b>,</b> </i> follow‐up lasted 12 weeks, the combination ICS/LABA was fluticasone and vilanterol 100/25 mcg once daily, and the LAMA was tiotropium 18 mcg once daily. We also identified one ongoing trial comparing budesonide/formoterol and tiotropium in patients with COPD and bronchiectases. </p> <p>Both included trials reported mortality. Deaths occurred only in the tiotropium group (four participants in total). In the main analysis, we did not demonstrate or exclude any differences between groups in mortality, but in an additional sensitivity analysis using the Peto odds ratio (OR), undertaken because deaths were a rare event, we showed that the difference favoured fluticasone/vilanterol. However, we have very low confidence in this effect estimate. Of note, death was not a primary endpoint in any of the included trials, and these studies might be underpowered to detect differences in mortality. </p> <p>Both included studies also assessed COPD exacerbations, pneumonia, and other serious adverse events (mainly of cardiovascular origin). Pneumonia was observed only in the fluticasone/vilanterol group (five participants in total), and in the main analysis we did not demonstrate or exclude any differences between groups, but as above, in an additional sensitivity analysis using the Peto OR, we showed the difference in favour of tiotropium. As for mortality, evidence of very low quality greatly reduces our certainty in this finding. Differences for COPD exacerbations and other serious events could neither be demonstrated nor excluded. All these endpoints were not assessed as primary in the included trials; therefore the population may have been too small to show statistically significant differences. </p> <p>Included studies assessed quality of life using St George's Respiratory Questionnaire (SGRQ) and noted improvement in all SGRQ components among both groups. However, the mean change difference between groups in total SGRQ was not significant. It is also uncertain whether improvement in symptoms measured by the COPD Assessment Test (CAT score; data available only in <a href="./references#CD012355-bbs2-0002" title="PepinJL , CockcroftJR , MidwinterD , SharmaS , RubinDB , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest2014;146(6):1521‐30. RubinDB , PepinJ‐L , CockcroftJR , MidwinterD , SharmaS , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187(Meeting Abstracts):A6027. ">Pepin 2014</a>), in hospital admissions (due to pneumonia, COPD exacerbation, or any reason), and in forced expiratory volume in one second (FEV₁) (change from baseline trough in 24‐hour weighted mean on treatment day 84) differs between compared treatment options. Only one study assessed the use of rescue medication (<a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a>), which was less in the ICS/LABA group. The included trials were not powered to detect differences in aforementioned outcomes, except for FEV₁, which was the primary outcome in one study (<a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a>). </p> <p>Included trials did not provide data for other prespecified endpoints (exacerbations leading to intubation and physical activity measure; e.g. results of six‐minute walk test (6MWT)). </p> <p>In conclusion, our review shows neither major differences between ICS/LABA and LAMA nor equivalence of these treatments in patients with COPD, and a high degree of uncertainty is associated with evidence of very low quality for all assessed outcomes. </p> </section> <section id="CD012355-sec-0090"> <h3 class="title" id="CD012355-sec-0090">Overall completeness and applicability of evidence</h3> <p>Participants and reported outcomes are typical for patients with COPD, except for the arterial stiffness parameter (aortic pulse wave velocity (aPWV) in one study ‐ <a href="./references#CD012355-bbs2-0002" title="PepinJL , CockcroftJR , MidwinterD , SharmaS , RubinDB , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest2014;146(6):1521‐30. RubinDB , PepinJ‐L , CockcroftJR , MidwinterD , SharmaS , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187(Meeting Abstracts):A6027. ">Pepin 2014</a>).and the requirement for all participants to have either a history of a cardiovascular disease (CVD) event, or at least one additional CVD risk factor (one study ‐ <a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a>). However, included trials were focused on and were powered for surrogate outcomes (FEV₁ in <a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a>, and aPWV in <a href="./references#CD012355-bbs2-0002" title="PepinJL , CockcroftJR , MidwinterD , SharmaS , RubinDB , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest2014;146(6):1521‐30. RubinDB , PepinJ‐L , CockcroftJR , MidwinterD , SharmaS , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187(Meeting Abstracts):A6027. ">Pepin 2014</a>), and their aims differed from the aims of this review. In addition, follow‐up lasted only 12 weeks in both trials. This limits the practical value of evidence related to clinically important (patient‐centred) outcomes. Data on mortality are most strongly affected, in that mortality was obviously low during such a short time. Twelve weeks' follow‐up also impairs the applicability of evidence for COPD exacerbations, hospital admissions, pneumonia, and other serious adverse events. Follow‐up prolonged to at least six months, preferably with annualised results, would be more appropriate for these rarer endpoints. In addition, data synthesis was limited by lack of common data for some outcomes, namely, use of rescue medication and some adverse events. Moreover, assessments of some other endpoints important for patients with COPD, such as admissions to intensive care units (exacerbations leading to intubation) and measures of physical activity (e.g. 6MWT), are lacking. Finally, lack of data prevented us from performing planned subgroup and sensitivity analyses. For future reviews involving more studies, a priori subgroups might also include, for example, peripheral blood eosinophil count. </p> </section> <section id="CD012355-sec-0091"> <h3 class="title" id="CD012355-sec-0091">Quality of the evidence</h3> <p>We assessed the overall quality of evidence as very low for all outcomes. Both included trials were industry sponsored. We downgraded quality by one level for risk of bias because of some limitations for multiple criteria that are sufficient to lower confidence in the estimate of effect despite the absence of high risk ratings. Specifically, selection bias was unclear in one study owing to lack of information on methods of random sequence generation and allocation concealment (<a href="./references#CD012355-bbs2-0002" title="PepinJL , CockcroftJR , MidwinterD , SharmaS , RubinDB , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest2014;146(6):1521‐30. RubinDB , PepinJ‐L , CockcroftJR , MidwinterD , SharmaS , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187(Meeting Abstracts):A6027. ">Pepin 2014</a>). Moreover, we assessed risk of performance and detection bias in both studies as unclear for subjective outcomes because imperfect methods of blinding were reported (<a href="./references#CD012355-bbs2-0001" title="CovelliH , PekB , SchenkenbergerI , Scott‐WilsonC , EmmettA , CrimC . Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of Chronic Obstructive Pulmonary Disease2016;11:1‐12. [DOI: 10.2147/COPD.S91407] ">Covelli 2016</a>; <a href="./references#CD012355-bbs2-0002" title="PepinJL , CockcroftJR , MidwinterD , SharmaS , RubinDB , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest2014;146(6):1521‐30. RubinDB , PepinJ‐L , CockcroftJR , MidwinterD , SharmaS , AndreasS . Long‐acting bronchodilators and arterial stiffness in patients with COPD. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187(Meeting Abstracts):A6027. ">Pepin 2014</a>). Finally, we judged risk of attrition bias as unclear in both trials despite intention‐to‐treat analyses of their primary outcomes, because secondary outcome results were not described for all participants, and it is not clear how researchers handled missing data. </p> <p>Because typical patients with COPD participated in both included trials, the quality of evidence was not influenced by indirectness. We also did not detect significant heterogeneity (inconsistency) between studies. However, the quality of evidence was strongly affected by imprecision for all outcomes, and we lowered the ratings by two levels because small numbers of events and limited numbers of participants resulted in wide (or very wide) confidence intervals, including significant benefits and harms, and/or the optimal information size criterion was not met (or numbers of events were too low for reliable calculation of optimal information size). </p> <p>We were not able to assess publication bias using funnel plots owing to the small number (only two) of included trials. Paucity of studies also precluded subgroup analyses and sensitivity analysis for risk of bias, which we had pre‐planned in the protocol of our review (<a href="./references#CD012355-bbs2-0071" title="SliwkaA , JankowskiM , Gross‐SondejI , NowobilskiR , BalaMM . Once daily Long‐acting beta2‐agonists/Inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic antagonists for people with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2016, Issue 9. [DOI: 10.1002/14651858.CD012355] ">Sliwka 2016</a>). </p> </section> <section id="CD012355-sec-0092"> <h3 class="title" id="CD012355-sec-0092">Potential biases in the review process</h3> <p>We performed an exhaustive search of the published and unpublished literature for potentially relevant clinical trials by applying a systematic search strategy. Trial selection and data extraction followed a prespecified protocol and were independently conducted by two review authors (<a href="./references#CD012355-bbs2-0071" title="SliwkaA , JankowskiM , Gross‐SondejI , NowobilskiR , BalaMM . Once daily Long‐acting beta2‐agonists/Inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic antagonists for people with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2016, Issue 9. [DOI: 10.1002/14651858.CD012355] ">Sliwka 2016</a>). Despite all these efforts, additional unidentified trials may exist. </p> </section> <section id="CD012355-sec-0093"> <h3 class="title" id="CD012355-sec-0093">Agreements and disagreements with other studies or reviews</h3> <p>Our review is the first to compare a once‐daily combination of inhaled corticosteroid and long‐acting beta₂‐agonist inhalers (ICS/LABA) versus inhaled long‐acting muscarinic antagonists alone (LAMA) in people with chronic obstructive pulmonary disease (COPD). </p> <p>A previous Cochrane Review compared the combination of inhaled steroid and long‐acting beta₂‐agonist taken twice daily versus tiotropium (<a href="./references#CD012355-bbs2-0069" title="WelshEJ , CatesCJ , PooleP . Combination inhaled steroid and long‐acting beta2‐agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD007891.pub3] ">Welsh 2013</a>). This review was based mainly on the Investigating New Standards for Prophylaxis in Reducing Exacerbations (INSPIRE) trial, and review authors were unable to reach any definitive conclusions. According to the INSPIRE trial, twice‐daily combinations of salmeterol and fluticasone propionate when compared with once‐daily tiotropium seemed to have a similar effect on the overall exacerbation rate, although fewer dropouts and deaths and a better health status were recorded in the combination group (<a href="./references#CD012355-bbs2-0067" title="WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AsariZ , StockleyRA . The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. American Journal of Respiratory and Critical Care Medicine2008;177(1):19‐26. ">Wedzicha 2008</a>). However, withdrawal rates were high (as is usual for COPD trials lasting longer than six months) and were unbalanced between arms, and people who dropped out were not followed up. This reduced the certainty of the effect; therefore the efficacy and safety of combined ICS/LABA compared to tiotropium remained uncertain. In our review, the combination of vilanterol trifenate and fluticasone furoate in comparison to tiotropium alone did not improve health‐related quality of life but reduced the use of rescue medication. </p> <p>Three other Cochrane Reviews may bring us indirect comparisons of treatment efficacy. A network meta‐analysis of long‐acting inhaled therapies for COPD including beta₂‐agonists, anticholinergics, and steroids included a node for combination of ICS and LABA administered twice daily (<a href="./references#CD012355-bbs2-0044" title="KewKM , DiasS , CatesCJ . Long‐acting inhaled therapy (beta‐agonists, anticholinergics and steroids) for COPD: a network meta‐analysis. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD010844.pub2] ">Kew 2014</a>). Review authors found the ICS/LABA combination as the most likely treatment strategy to bring the greatest improvement to quality of life and lung function at six months and ranked LAMA second at this time point, which is compatible with our observations according to quality of life. </p> <p>Nannini et al reviewed 19 randomised controlled trials (RCTs) assessing the efficacy and safety of combined inhaled steroids and long‐acting beta₂‐agonists versus placebo for treatment of COPD (<a href="./references#CD012355-bbs2-0056" title="NanniniLJ , PooleP , MilanSJ , KestertonA . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD006826.pub2] ">Nannini 2013</a>). Combined therapy reduced the rate of moderate exacerbations, but it did not translate to a significant reduction in hospitalisation rate. Also, small benefit over placebo in effects on health‐related quality of life, symptoms, lung function, and use of rescue medication was reported. Adverse effects, particularly pneumonia, were more common in the treatment groups than in the placebo groups, but exclusion of the Towards a Revolution in COPD Health (TORCH) trial showed that an excess of pneumonia was seen only with fluticasone propionate/salmeterol ‐ not with the other combined inhalers. ICS alone could be responsible for an increased mortality rate, as was shown in the TORCH fluticasone monotherapy arm versus the ICS/LABA combination arm at the end of the trial (<a href="./references#CD012355-bbs2-0027" title="CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. ">Calverley 2007</a>). This finding is concordant with the observations of our review because in an additional sensitivity analysis using the Peto odds ratio (OR) due to rare events, we showed statistically significantly increased risk of pneumonia in the fluticasone/vilanterol group and no differences in other non‐fatal serious adverse events as compared with the tiotropium group. </p> <p>Rojas‐Reyes et al reviewed six RCTs with low risk of bias that compared tiotropium in addition to ICS/LABA combination versus tiotropium alone (<a href="./references#CD012355-bbs2-0061" title="Rojas‐ReyesMX , Garcia MoralesOM , DennisRJ , KarnerC . Combination inhaled steroid and long‐acting beta2‐agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2016, Issue 6. [DOI: 10.1002/14651858.CD008532.pub3] ">Rojas‐Reyes 2016</a>). Review authors found no statistically significant differences in mortality between treatments nor in all‐cause hospitalisations. Health‐related quality of life and lung function tests showed significant improvement in the combination treatment group as compared with the tiotropium alone group. At the same time, review authors found no significant differences in adverse events, serious adverse events, or pneumonia due to rare events between treatment groups, which is compatible with our observations, except for mortality and pneumonia in the additional sensitivity analysis based on Peto ORs. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012355-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/urn:x-wiley:14651858:media:CD012355:CD012355-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_t/tCD012355-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012355-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/full#CD012355-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012355-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/urn:x-wiley:14651858:media:CD012355:CD012355-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_t/tCD012355-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012355-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/full#CD012355-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012355-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/urn:x-wiley:14651858:media:CD012355:CD012355-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_t/tCD012355-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012355-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/full#CD012355-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012355-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/urn:x-wiley:14651858:media:CD012355:CD012355-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_t/tCD012355-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), outcome: 1.1 Mortality all‐cause." data-id="CD012355-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), outcome: 1.1 Mortality all‐cause. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/full#CD012355-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012355-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/urn:x-wiley:14651858:media:CD012355:CD012355-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_t/tCD012355-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), outcome: 1.2 Any COPD exacerbation that requires short‐burst oral corticosteroids or antibiotics, or both." data-id="CD012355-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), outcome: 1.2 Any COPD exacerbation that requires short‐burst oral corticosteroids or antibiotics, or both. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/full#CD012355-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012355-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/urn:x-wiley:14651858:media:CD012355:CD012355-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_t/tCD012355-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Once daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists(TIO), outcome: 1.3 Pneumonia." data-id="CD012355-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Once daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists(TIO), outcome: 1.3 Pneumonia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/full#CD012355-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012355-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/urn:x-wiley:14651858:media:CD012355:CD012355-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_t/tCD012355-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), outcome: 1.4 Total, serious adverse events." data-id="CD012355-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), outcome: 1.4 Total, serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/full#CD012355-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012355-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/urn:x-wiley:14651858:media:CD012355:CD012355-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_t/tCD012355-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Once‐daily long‐acting beta2‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), Outcome 1 Mortality all‐cause." data-id="CD012355-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Once‐daily long‐acting beta<sub>2</sub>‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), Outcome 1 Mortality all‐cause. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/references#CD012355-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012355-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/urn:x-wiley:14651858:media:CD012355:CD012355-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_t/tCD012355-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Once‐daily long‐acting beta2‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), Outcome 2 Any COPD exacerbation that requires short‐burst oral corticosteroids or antibiotics, or both." data-id="CD012355-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Once‐daily long‐acting beta<sub>2</sub>‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), Outcome 2 Any COPD exacerbation that requires short‐burst oral corticosteroids or antibiotics, or both. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/references#CD012355-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012355-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/urn:x-wiley:14651858:media:CD012355:CD012355-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_t/tCD012355-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Once‐daily long‐acting beta2‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), Outcome 3 Pneumonia." data-id="CD012355-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Once‐daily long‐acting beta<sub>2</sub>‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), Outcome 3 Pneumonia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/references#CD012355-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012355-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/urn:x-wiley:14651858:media:CD012355:CD012355-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_t/tCD012355-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Once‐daily long‐acting beta2‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), Outcome 4 Total, serious adverse events." data-id="CD012355-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Once‐daily long‐acting beta<sub>2</sub>‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), Outcome 4 Total, serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/references#CD012355-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012355-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/urn:x-wiley:14651858:media:CD012355:CD012355-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_t/tCD012355-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Once‐daily long‐acting beta2‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), Outcome 5 Quality of life: SGRQ." data-id="CD012355-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Once‐daily long‐acting beta<sub>2</sub>‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), Outcome 5 Quality of life: SGRQ. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/references#CD012355-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012355-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/urn:x-wiley:14651858:media:CD012355:CD012355-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_t/tCD012355-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Once‐daily long‐acting beta2‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), Outcome 6 Quality of life: improvement by the MCID after 12 weeks." data-id="CD012355-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Once‐daily long‐acting beta<sub>2</sub>‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), Outcome 6 Quality of life: improvement by the MCID after 12 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/references#CD012355-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012355-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/urn:x-wiley:14651858:media:CD012355:CD012355-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_t/tCD012355-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Once‐daily long‐acting beta2‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), Outcome 7 Hospital admissions." data-id="CD012355-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Once‐daily long‐acting beta<sub>2</sub>‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), Outcome 7 Hospital admissions. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/references#CD012355-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012355-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/urn:x-wiley:14651858:media:CD012355:CD012355-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_t/tCD012355-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Once‐daily long‐acting beta2‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), Outcome 8 Disease‐specific adverse events other than pneumonia." data-id="CD012355-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Once‐daily long‐acting beta<sub>2</sub>‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), Outcome 8 Disease‐specific adverse events other than pneumonia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/references#CD012355-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012355-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/urn:x-wiley:14651858:media:CD012355:CD012355-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_t/tCD012355-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Once‐daily long‐acting beta2‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), Outcome 9 CAT score difference at 12 weeks." data-id="CD012355-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Once‐daily long‐acting beta<sub>2</sub>‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), Outcome 9 CAT score difference at 12 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/references#CD012355-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012355-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/urn:x-wiley:14651858:media:CD012355:CD012355-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_t/tCD012355-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Once‐daily long‐acting beta2‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), Outcome 10 Trough FEV1." data-id="CD012355-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Once‐daily long‐acting beta<sub>2</sub>‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO), Outcome 10 Trough FEV1. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/references#CD012355-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012355-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/urn:x-wiley:14651858:media:CD012355:CD012355-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_t/tCD012355-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analyses for rare events, Outcome 1 Mortality all‐cause." data-id="CD012355-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analyses for rare events, Outcome 1 Mortality all‐cause.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/references#CD012355-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012355-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/urn:x-wiley:14651858:media:CD012355:CD012355-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_t/tCD012355-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analyses for rare events, Outcome 2 Pneumonia." data-id="CD012355-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analyses for rare events, Outcome 2 Pneumonia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/references#CD012355-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/media/CDSR/CD012355/image_n/nCD012355-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012355-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Once‐daily ICS/LABA combined inhalers compared to once‐daily LAMA for people with chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Once‐daily ICS/LABA combined inhalers compared to once‐daily LAMA for people with chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with chronic obstructive pulmonary disease<br/> <b>Setting:</b> studies were conducted at 102 medical centres in 11 countries (Canada, Czech Republic, Germany, Poland, Romania, USA, Argentina, France, Italy, Norway, Russian Federation, Ukraine)<br/> <b>Intervention:</b> once‐daily inhaled corticosteroids/long‐acting beta₂‐agonists combined inhalers (FF/VI)<br/> <b>Comparison:</b> inhaled long‐acting muscarinic antagonist (TIO) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with inhaled long‐acting muscarinic antagonist (TIO)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers (FF/VI)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality (all‐cause)<br/> Follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.20<br/> (0.02 to 1.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>880<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any COPD exacerbation that requires short‐burst oral corticosteroids or antibiotics, or both<br/> Follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000<br/> (15 to 60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.72<br/> (0.35 to 1.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>880<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pneumonia</p> <p>Follow‐up: 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 6.12<br/> (0.73 to 51.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>880<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> assessed with SGRQ </p> <p>Mean change from baseline, scale 0‐100, low on the scale is better QoL<br/> Follow‐up: 12 weeks. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change from baseline in quality of life was</p> <p>–4.97 in one study</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.29 lower<br/> (3.01 lower to 0.42 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>779<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 1 study provided information on mean change from baseline in each group; the other study reported only differences between groups </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital admissions (all‐cause)<br/> Follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000<br/> (20 to 74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.96<br/> (0.49 to 1.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>880<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbations leading to intubation</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Physical activity measure<br/> (e.g. 6MWT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> <br/> 6MWT: 6‐Minute Walking Test; CI: confidence interval; COPD: chronic obstructive pulmonary disease; FF: fluticasone furoate; ICS: inhaled corticosteroids; LABA: long‐acting beta₂‐agonists; LAMA: long‐acting muscarinic antagonists; OR: odds ratio; QoL: quality of life; RCT: randomised controlled trial; SGRQ: St George's Respiratory Questionnaire; TIO: tiotropium; VI: vilanterol </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded for risk of bias by one level because both studies had unclear risk of bias for blinding and incomplete outcome data and one study did not provide information on methods of randomisation and concealment </p> <p><sup>b</sup>We downgraded for imprecision by two levels because very low number of events leads to wide 95% CIs, and the number of events was too low to reliably calculate optimal information size </p> <p><sup>c</sup>We downgraded for imprecision by two levels because the optimal information size criterion is not met and the 95% CI is wide including significant benefit and harm </p> <p><sup>d</sup>We downgraded for imprecision by two levels owing to very wide 95% CIs including significant benefit and harm </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Once‐daily ICS/LABA combined inhalers compared to once‐daily LAMA for people with chronic obstructive pulmonary disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/full#CD012355-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012355-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other serious adverse events</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Coveli 2015</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FF/VI, n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIO, n (%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Cardiac disorders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Cardio‐respiratory arrest</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/313 (0.64)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Acute myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/313 (0.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Cardiac failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/313 (0.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Cardiac failure congestive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/313 (0.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Infections and infestations</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Urinary tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/310 (0.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/313 (0.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Graft infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/313 (0.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Post‐procedural infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/310 (0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/313 (0.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Injury, poisoning, and procedural complications</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Alcohol poisoning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/313 (0.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Anaemia postoperative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/310 (0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/313 (0.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Cardiac procedure complication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/313 (0.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Patella fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/310 (0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/313 (0.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Metabolism and nutrition disorders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Dehydration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/313 (0.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Hypercholesterolaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/313 (0.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Neoplasms benign, malignant and unspecified (including cysts and polyps)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Pancreatic carcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/310 (0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/313 (0.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Nervous system disorders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Epilepsy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/313 (0.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Psychiatric disorders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Alcohol abuse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/313 (0.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/313 (0.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Vascular disorders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Blood pressure fluctuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/310 (0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/313 (0.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Leriche syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/310 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/313 (0.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Thrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/310 (0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/313 (0.00)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Pepin 2014</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FF/VI, n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIO, n (%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Gastrointestinal disorders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Acute abdomen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/127 (0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/130 (0.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Pancreatolithiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/127 (0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/130 (0.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>General disorders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/127 (0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/130 (0.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Hepatobiliary disorders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Bile duct obstruction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/127 (0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/130 (0.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Infections and infestations</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Peritonsillar abscess</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/127 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/130 (0.77)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Injury, poisoning, and procedural complications</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Multiple injuries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/127 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/130 (0.77)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Neoplasms benign, malignant, and unspecified (including cysts and polyps)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Bronchial carcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/127 (0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/130 (0.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Nervous system disorders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Altered state of consciousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/127 (0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/130 (0.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Respiratory, thoracic, and mediastinal disorders</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Pulmonary embolism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/127 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/130 (0.77)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Skin and subcutaneous tissue disorders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Skin ulcer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/127 (0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/130 (0.77)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>FF: fluticasone furoate; TIO: tiotropium; VI: vilanterol.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/full#CD012355-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012355-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Other adverse events</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Covelli 2015</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Pepin 2014</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FF/VI, n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIO, n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FF/VI, n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIO, n (%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total, other (not including serious) adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/310 (10.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32/313 (10.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/127 (6.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/130 (6.15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Infections and infestations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Nasopharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/310 (5.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/313 (4.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/127 (3.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/130 (3.08)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Nervous system disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/310 (5.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/313 (7.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/127 (2.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/130 (3.85)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>FF: fluticasone furoate; TIO: tiotropium; VI: vilanterol.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Other adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/full#CD012355-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012355-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Once‐daily long‐acting beta2‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality all‐cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.02, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Any COPD exacerbation that requires short‐burst oral corticosteroids or antibiotics, or both <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.35, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Exacerbation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.29, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Exacerbation or worsening</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.22, 2.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.12 [0.73, 51.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total, serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.50, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Quality of life: SGRQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>779</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.29 [‐3.01, 0.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Quality of life: improvement by the MCID after 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Hospital admissions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Pneumonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.14 [0.60, 44.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Exacerbation COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.13, 6.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Hospitalisation for any reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.49, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Disease‐specific adverse events other than pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Lower respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.25, 3.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Cardiovascular effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.43, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Local steroid effects/candidiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [0.83, 3.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Bone disorders/fractures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.06 [0.48, 19.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Ocular effects/glaucoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.11, 9.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 Any adverse events (not including serious)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.62, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 CAT score difference at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Trough FEV1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>741</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.02, 0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Once‐daily long‐acting beta2‐agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long‐acting muscarinic antagonists (TIO)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/references#CD012355-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012355-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Sensitivity analyses for rare events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality all‐cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.02, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.56 [1.30, 43.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Sensitivity analyses for rare events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012355.pub2/references#CD012355-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012355.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012355-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012355-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012355-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD012355-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012355-note-0005">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD012355-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012355-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012355\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012355\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012355\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012355\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012355\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012355\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012355\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012355\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012355\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012355\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012355\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012355\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012355\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012355\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012355\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012355\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012355\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012355\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=l7AWCCEw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012355.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012355.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012355.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012355.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012355.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726232063"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012355.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726232067"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012355.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e8e9e28c1f431',t:'MTc0MDcyNjIzMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 